

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 May 2002 (02.05.2002)

PCT

(10) International Publication Number  
**WO 02/34287 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K 39/00**
- (21) International Application Number: PCT/DK01/00705
- (22) International Filing Date: 26 October 2001 (26.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
PA 2000 01606 27 October 2000 (27.10.2000) DK  
60/245,166 3 November 2000 (03.11.2000) US  
PA 2001 00936 18 June 2001 (18.06.2001) DK
- (71) Applicant (*for all designated States except US*):  
**PHARMEXA A/S** [DK/DK]; Kogle Allé 6, DK-2970  
Hørsholm (DK).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **BEIER, Anne, Mette** [DK/DK]; c/o Pharmexa A/S, Kogle Allé 6, DK-2970 Hørsholm (DK). **GAUTAM, Anand** [GB/DK]; c/o Pharmexa A/S, Kogle Allé 6, DK-2970 Hørsholm (DK). **MOURITSEN, Søren** [DK/DK]; c/o Pharmexa A/S, Kogle Allé 6, DK-2970 Hørsholm (DK).
- (74) Agent: **KOEFOED, Peter**; c/o Pharmexa A/S, Kogle Allé 6, DK-2970 Hørsholm (DK).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EC, EE, ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: NOVEL THERAPEUTIC VACCINE FORMULATIONS

(57) Abstract: The present invention relates to a novel method and formulation for the induction of immune responses against polypeptide antigens. In particular, the invention provides a method and formulation for induction of cytotoxic T cell responses against a polypeptide antigen of choice. The formulations are characterized by containing chitosan in admixture with the polypeptide antigen, preferably in the form of microparticles that may be cross-linked.

WO 02/34287 A2

## NOVEL THERAPEUTIC VACCINE FORMULATIONS

## FIELD OF THE INVENTION

The present invention relates to novel methods for combatting diseases, such as cancers, which are characterized by the presence of gene expression products which are non-immunogenic or poorly immunogenic. In particular, the present invention relates to methods for inducing an immune response conducted by cytotoxic T-lymphocytes (CTLs), whereby cells carrying epitopes from the gene expression products are attacked and killed by the CTLs. The invention specifically relates to formulation in chitosan and other chitin-derivatives of self-proteins and "immunogenized" self-proteins in order to provide for enhanced specific immune responses, especially enhanced CTL responses.

Hence, the invention relates to a series of applications of vaccination technology, e.g. within the field of therapeutic vaccination against cancer, but also within the general field of protein vaccination where CTL responses are desired.

## BACKGROUND OF THE INVENTION

The idea of vaccinating against cancer has been around for more than hundred years and has enjoyed recurrent bursts of activity, particularly since the turn of this century.

However, during the past 10 years the understanding of the fundamental molecular mechanisms of the immune response has improved considerably. Among the most important milestones achieved during this period has been the discovery of the still growing list of cytokines and growth factors, the under-

standing of the mechanisms of interaction between T and B cells as well as the establishment of the cellular antigen processing pathways including the role and structure of the MHC class I and II molecules in antigen presentation. Important discoveries with regard to cancer immunology - although still not fully understood - were also the elucidation of the mechanisms underlying induction of immunological tolerance in a host. All this research has led to a huge amount of efforts in order to develop new treatments for human cancer.

- 10 Depending on how tumour immunity is acquired by the patient, immunotherapy regimens can be categorised as either passive or active. In passive immunotherapy regimens the patient passively receives immune components such as cytokines, antibodies, cytotoxic T-cells, or lymphocyte activated killer (LAK) cells.
- 15 In contrast, active specific immunotherapy protocols encompass actively inducing tumour immunity by vaccination with the tumour cell or its antigenic components. This latter form of treatment is preferred because the immunity is prolonged.

- Passive and active cancer vaccines have focussed on inducing either humoral or cellular immune responses. For active vaccines it is well established that induction of CD4 positive T helper cells is necessary in order to secondarily induce either antibodies or cytotoxic CD8 positive T cells.

#### *Passive vaccination with antibodies*

- 25 Since the discovery of the monoclonal antibody technology in the mid-seventies, a large number of therapeutic monoclonal antibodies directed against tumour specific or tumour associated antigens has been developed. Monoclonal antibody therapy, however, gives rise to several serious problems:

- Injection of these foreign substances induces an immune response in the patient towards the injected antibodies, which may lead to less efficient treatment as well as to serious allergic side-effects in the patients.
- 5 - Monoclonal antibodies usually must be administered in large amounts. This is a problem, since the production costs of monoclonal antibodies are huge.
- Monoclonal antibodies must be administered via the parenteral route and due to the relatively large amounts needed, the  
10 patients frequently must be hospitalised during the treatment.
- Injections of monoclonal antibodies must be repeated at rather short intervals (weeks) in order to maintain therapeutic effect.
- Monoclonal antibodies are usually not able to activate  
15 secondary effector systems of the immune system such as complement, NK-cells or macrophage killing of tumour cells.

The latter disadvantage is of particular importance in cancer therapy and may be an important reason why monoclonal antibody therapy of cancer in several cases has not been particularly  
20 successful. The so-called humanised monoclonal antibodies now used by many companies are less immunogenic, but unfortunately they are even less capable of activating the secondary immune effector systems. Furthermore, examples of secondary out-growth of tumours lacking the original tumour antigen have  
25 been observed, since these antibodies do not induce "innocent bystander" effects on tumour cells not carrying the tumour antigen.

The poor effector capability of the monoclonal antibodies has led to the development of monoclonal antibodies chemically conjugated to different toxins and radioisotopes. Pharmacia Upjohn AB has e.g. developed a conjugate between a monoclonal  
5 tumour specific antibody and the *Staphylococcus aureus* toxin A with the purpose of activating T cells in the tumour. Medarex Inc. has developed bispecific monoclonal antibodies containing a tumour specific Fab fragment as well as an Fc-receptor specific antibody fragment with the purpose of activating  
10 macrophage killing of tumour cells. Both constructs are more effective than the monoclonal antibody alone, but they are also more expensive and immunogenic. Antibodies conjugated to radioisotopes are also expensive as well as immunogenic and other general toxic side-effects are observed.

15 The appearance of the monoclonal antibody technology was a major step forward which enabled the production of well-defined, high-affinity binding molecules. However, being monoclonal these antibodies only react with a single type of epitope on a tumour antigen. This is the major reason why they  
20 usually are not able to activate the complement system or binding to the Fc-receptors of NK-cells and macrophages. These very powerful effector systems usually require the co-localisation of multiple Fc antibody fragments protruding from the antigen.

25 Other researchers have therefore attempted to use two monoclonal antibodies in combination and this has led to an improved effect. It therefore seems very reasonable instead to attack tumour cells with highly specific polyclonal antibodies directed against a tumour specific, or against (over-expressed)  
30 tumour associated antigens or-growth factor receptors. Such antibodies would be fully capable of activating the secondary

effector systems mentioned above. Furthermore, it is likely that the local inflammatory reaction induced by these effector systems could lead to secondary effects on "innocent bystander" cells not expressing the tumour antigen in question  
5 as well as to activation of tumour specific TIL's (tumour infiltrating lymphocytes) in the tumour tissue. Such effects have been observed by Medarex Inc. using their bi-specific monoclonal antibody conjugates.

Since the discovery of the monoclonal antibody technology the  
10 potential use of polyclonal antibodies for cancer therapy has not been explored very much (except for the antigens described below). One major reason is that well-defined tumour specific or tumour associated surface antigens only have been characterised within the recent years, but - more importantly - many  
15 of these have turned out to be self-antigens and therefore non-immunogenic. Accordingly, xenogenic polyclonal antibodies would necessarily have been used to study the effects. However, such antibodies induce a vigorous immune response towards the injected foreign polyclonal antibodies which rapidly  
20 eliminate the therapeutic effects.

#### *Active vaccination to induce antibodies*

Recent attempts to induce therapeutic polyclonal autoantibodies in cancer patients by active vaccination have been successful. Vaccines against membrane bound carbohydrate self-  
25 antigens (such as the O-linked aberrantly expressed Tn and sTn-antigens and the ganglioside liposaccharides GM2 and GD3) have been developed. These small carbohydrate structures are, however, very poor antigens so conjugates of these molecules with carrier molecules such as keyhole limpet haemocyanin  
30 (KLH) or sheep mucins (containing Tn- and sTn) must be used.

In melanoma patients the induction of anti-GM2 antibodies were associated with a prolonged disease-free interval and overall survival after a minimum follow-up of fifty-one months. Also randomised phase II studies have been conducted on breast  
5 cancer patients using a conjugate of sTn and KLH in the DETOX-B adjuvant (BIOMIRA Inc.) showing that sTn immune patients had a significantly longer median survival compared to controls. Another example of the active induction of polyclonal antibodies in cancer is the use of idiotype specific vaccination  
10 against B-cell lymphomas, which - although it has been promising - is limited to this cancer type only.

Finally, the US company Aphton Inc. has developed active conjugate vaccines against gonadotropin releasing hormone (GnRH) and gastrin. It has been demonstrated, that this vac-  
15 cine is capable of controlling the biological activity of these hormones, which also can function as autocrine growth factors for certain tumour cells. Successful phase II clinical trials have been conducted on gastrointestinal cancer patients and phase III clinical trials are underway.

## 20 *Cytotoxic T-cells*

It has been clearly demonstrated by several groups that tumour specific cytotoxic T cells (CTL's) are present in many tumours. These CTL's are termed tumour infiltrating lymphocytes (TIL's). However, these cells are somehow rendered non-respon-  
25 sive or anergic by several different possible mechanisms including secretion of immunosuppressive cytokines by the tumour cells, lack of co-stimulatory signals, down regulation of MHC class I molecules etc.

There has been many attempts to isolate the tumour specific  
30 HLA class I bound peptides recognised by TILs, and in some

cases it has also been successful (e.g. peptides from the melanoma associated antigens). Such peptides have been used to induce a tumour specific immune response in the host, but the practical use of tumour specific peptides in vaccines is  
5 restricted to a limited segment of the population due to the narrow HLA class I binding specificity of the peptides. Furthermore, it is usually relatively difficult to evoke a CTL response *in vivo* using synthetic peptides due to the low biological half-life of these substances as well as the diffi-  
10 culties with exogenous priming of MHC class I molecules.

Many other approaches have been attempted in order to evoke a tumour specific CTL response including the use of cytokines (e.g. IL-2, IFN- $\gamma$ , IL-6, IL-4, IL-10 or GM-CSF) or co-stimulatory molecules (B7) either in soluble form or expressed  
15 by the transfected tumour cell. Furthermore, immunisations with allogenic or autologous whole cells, or of tumour antigens prepared in specialised adjuvants designed to present the antigen via the MHC class I antigen presentation route, or tumour antigens expressed in e.g. vaccinia vectors etc. have  
20 been used with varying success. Still the general belief among tumour immunologists is therefore that one of the best ways to eliminate tumours would be to induce a strong specific anti-tumour CTL response.

Apart from the fact that these treatments usually are very  
25 expensive and difficult to reproduce, it has also turned out to be difficult to obtain a good immune response towards the tumour since many of the tumour associated antigens are true self-proteins to which most T cells appear to be tolerant. Therefore, it seems necessary to induce a controlled cellular  
30 autoimmune condition in the patient.

## OBJECT OF THE INVENTION

It is an object of the present invention to provide improved methods and agents for inducing immune responses in host organisms against undesirable antigens, e.g. tumour antigens.

- 5 In particular it is an object of the present invention to provide formulations of proteinaceous antigens that are capable of inducing effective CTL responses against these antigens.

## SUMMARY OF THE INVENTION

- 10 Presentation of antigens has dogmatically been thought of as two discrete pathways, a class II exogenous and a class I endogenous pathway.

- Briefly, a foreign protein from outside the cell or from the cell membrane is taken up by the APC as an endosome which  
15 fuses with an intracellular compartment which contains proteolytic enzymes and MHC class II molecules. Some of the produced peptides bind to class II, which then are translocated to the cell membrane.

- The class I endogenous pathway is characterised by the predominant presentation of cytosolic proteins. This is believed to  
20 occur by proteasome mediated cleavage followed by transportation of the peptides into the endoplasmic reticulum (ER) via TAP molecules located in the membrane of the ER. In ER the peptides bind to class I followed by transportation to the  
25 plasma membrane.

However, these 2 pathways are not fully distinct. For example it is known that dendritic cells and to some extent macrophages are capable of endocytosing (pinocytosing) extracellu-

lar proteins and subsequently present them in the context of MHC class I. It has also previously been demonstrated that using specialised administration routes, e.g. by coupling to iron oxide beads, exogenous antigens are capable of entering  
5 the Class I pathway (Rock, 1996). This mechanism seems central, because of the importance of a concomitant expression of both class I and class II on the same APC to elicit a three cell type cluster. This three cell type cluster of interaction has been proposed by Mitchison (1987) and later by other  
10 authors. They showed the importance of concomitant presentation of class I and class II epitopes on the same APC. According to the recently described mechanism for CTL activation (cf. Lanzavecchia, 1998, Nature 393: 413, Matzinger, 1999, Nature Med. 5: 616, Ridge et al., 1998, Nature 393: 474,  
15 Bennett et al., 1998, Nature 393: 478, Schoenberger et al., 1998, Nature 393: 480, Ossendrop et al., 1998, J. Exp. Med 187: 693, and Mackey et al., 1998, J. Immunol 161: 2094), professional APCs presenting antigen on MHC class II are recognized by T helper cells. This results in an activation of  
20 the APC (mediated by interaction by CD40L on the T helper cell and CD40 on the APC). This enables the APC to directly stimulate CTLs which are thereby activated. Cf. also Fig. 2.

It has previously been demonstrated that insertion of a foreign MHC class II restricted T helper cell epitope into a  
25 self-antigen results in the provision of an antigen capable of inducing strong cross-reactive antibody responses directed against the non-modified self-antigen (cf. applicant's WO 95/05849). It was shown that the autoantibody induction is caused by specific T cell help induced by the inserted foreign  
30 epitope.

However, we have come to the conclusion that modified self-antigens - with the aid of appropriate adjuvants - ought to be capable of also inducing strong CTL responses against MHC class I restricted self-epitopes and hence the technology described in WO 95/05849 can be adapted to also provide vaccination against intracellular and other cell-associated antigens which have epitopes presented in the context of MHC Class I. This inventive concept is the subject matter of WO 00/20027.

10 The autovaccine technology described in WO 95/05849 has the effect that specific T cell help is provided to self-reactive B cells when a modified self-antigen is administered for uptake into the MHC class II antigen processing pathway (cf. Fig. 1, and Dalum I *et al.*, 1996, *J. Immunol.* **157**: 4796-4804 as well as Dalum I *et al.*, 1999, *Nature Biotechnol.* **17**: 666-669). It was shown that potentially self-reactive B-lymphocytes recognizing self-proteins are physiologically present in normal individuals. However, in order for these B-lymphocytes to be induced to actually produce antibodies reactive with the relevant self-proteins, assistance is needed from cytokine producing T-helper lymphocytes ( $T_H$ -cells or  $T_H$ -lymphocytes). Normally this help is not provided because T-lymphocytes in general do not recognize T-cell epitopes derived from self-proteins when presented by antigen presenting cells (APCs).

25 However, by providing an element of "foreignness" in a self-protein (*i.e.* by introducing an immunologically significant modification), T-cells recognizing the foreign element are activated upon recognizing the foreign epitope on an APC (such as, initially, a mononuclear cell). Polyclonal B-lymphocytes (which present T-cell epitopes) capable of recognising self-epitopes on the modified self-protein also internalise the antigen and subsequently presents the foreign T-cell

epitope(s) thereof, and the activated T-lymphocytes subsequently provide cytokine help to these self-reactive polyclonal B-lymphocytes. Since the antibodies produced by these polyclonal B-lymphocytes are reactive with different epitopes  
5 on the modified polypeptide, including those which are also present in the native polypeptide, an antibody cross-reactive with the non-modified self-protein is induced. In conclusion, the T-lymphocytes can be led to act as if the population of polyclonal B-lymphocytes have recognised an entirely foreign  
10 antigen, whereas in fact only the inserted epitope(s) is/are foreign to the host. In this way, antibodies capable of cross-reacting with non-modified self-antigens are induced.

As mentioned above, CTL's also require specific T cell help, although the mechanism for this is still not completely clear.  
15 However, the invention disclosed in WO 00/20027 has demonstrated that self-proteins containing foreign MHC class II epitopes and entering the MHC class I antigen processing pathway of e.g. macrophages and dendritic cells induces a strong CTL response against subdominant epitopes in the self-  
20 protein. In essence there are two ways that such self-protein analogues can enter the Class I pathway: By use of nucleic acid immunization and by use of a formulation/adjuvant which effects uptake of the analogues into APCs so as to enter the Class I pathway.

25 The present invention primarily provides for such formulations/adjuvants that utilise various forms of chitin derivatives such as chitosan.

In conclusion, a vaccine constructed using the technology outlined above will induce a humoral autoantibody response  
30 with secondary activation of complement and antibody dependent

cellular cytotoxicity (ADCC) activity. It is also expected that it will induce a cytotoxic T cell response directed against e.g. a tumour specific membrane antigen, but it is according to the present invention concluded that this CTL  
5 response will be greatly facilitated if the polypeptide construct in question is formulated with a chitin derivative as described below.

Hence, in the broadest and most general scope, the present invention relates to a method for inducing or enhancing an  
10 immune response against a polypeptide antigen in an animal, including a human being, said polypeptide antigen being weakly immunogenic or non-immunogenic in the animal, the method comprising administering, to the animal, the polypeptide antigen or at least one variant thereof which includes foreign  
15 T-helper Cell epitopes ( $T_H$  epitopes) or at least one nucleic acid fragment encoding the polypeptide antigen or the at least one variant, wherein the polypeptide antigen or variant thereof or the nucleic acid fragment is formulated with chitosan.

20 In a more specific variant, this method comprises effecting simultaneous presentation by antigen presenting cells (APCs) from the animal's immune system of an immunogenically effective amount of

1) at least one CTL epitope derived from the polypeptide  
25 antigen and/or at least one B-cell epitope derived from the polypeptide antigen, and

2) at least one first T helper cell epitope ( $T_H$  epitope) which is foreign to the animal.

In a still further specific variant of the inventive method, the polypeptide antigen is a cell-associated polypeptide antigen which is sought down-regulated by inducing a specific cytotoxic T-lymphocyte (CTL) response against cells carrying  
5 the polypeptide antigen on their surface or harbouring the polypeptide antigen in their intracellular compartment, the method comprising effecting, in the animal, simultaneous presentation by a suitable antigen presenting cell (APC) of

- 1) at least one CTL epitope derived from the polypeptide  
10 antigen, and
- 2) at least one first T-helper lymphocyte ( $T_H$ ) epitope which is foreign to the animal.

The invention also relates to compositions comprising chitosan and a number of specific antigens or immunogenic variants of  
15 these antigens.

#### LEGENDS TO THE FIGURE

Fig. 1: The traditional AutoVac concept. A: Tolerodominant self-epitopes presented on MHC class II on an antigen presenting cell (APC) are ignored due to depletion in the T helper  
20 cell ( $T_H$ ) repertoire (T helper cell indicated with dotted lines). Inserted foreign immunodominant T cell epitopes presented on MHC class II activate T helper cells and B cells (B) specific for native parts of the self-protein presenting foreign immunodominant T cell epitopes on MHC class II are  
25 activated by the cytokine help provided by the T helper cell.

Fig. 2: The AutoVac concept for inducing a CTL response. Inserted foreign immunodominant T cell epitopes presented on

MHC class II activate T helper cells. CTL's recognising subdominant self-epitopes presented on MHC class I are activated by the adjacent activated T helper cell.

#### DETAILED DISCLOSURE OF THE INVENTION

##### 5 Definitions

In the following a number of terms used in the present specification and claims will be defined and explained in detail in order to clarify the metes and bounds of the invention.

- 10 "Chitosan", B (1,4) 2-amino-2-deoxy-D-glucose, denotes chitin and chitin-derived polysaccharides comprising co-polymers of glucosamine and N-acetylglucosamine. Different chitosans are characterized by molecular weight, viscosity and degree of deacetylation compared to chitin (chitosan is obtained by
- 15 alkaline hydrolysis of aminoacetyl groups of chitin). The term chitosan also includes within its scope "chitosan based compounds", i.e. derivatives or analogues of chitin and chitosan that are capable of forming suitable compositions with a polypeptide or a nucleic acid. Such an analogue of
- 20 derivative may be a modified chitosan or chitin, where the modification serves to alter the physical, chemical or physiological properties thereof. Such an analogue can be formed by non-covalent adherence due to electrostatic and/or hydrophilic and/or hydrophobic interactions or by covalent
- 25 bonding to chitosan or chitin. Examples of analogues include, but are not limited to, chitosan or chitin modified by having bound thereto specific or non-specific targeting ligands and/or membrane permeabilisation agents and/or endosomolytic agents and/or nuclear localisation signals. Other examples are

derivatized chitin or chitosan or the above mentioned analogues, *i.e.* O-acetylated and/or N-acetylated and/or N-trimethylated chitin, chitosan, or analogues. Finally, also included are salts of all these chitosan-based compounds, *e.g.* sulfate, phosphate, glutamate, chloride and tripolyphosphate salts (Berthold *et al.* 1996; Roy *et al.* 1999; Mao *et al.* 2001; van der Lübben *et al.* 2001).

The chitosan based compounds may advantageously be cross-linked, either naturally or by means of cross-linking or gelling agents such as glutaraldehyde (Akbuga and Durmaz 1994; Aiedeh *et al.* 1997; Jameela *et al.* 1995), formaldehyde or alginate gelation (Liu *et al.* 1997; Alexakis *et al.* 1995; Polk *et al.* 1994).

A "cell-associated polypeptide antigen" is in the present specification and claims intended to denote a polypeptide which is confined to a cell which is somehow related to a pathological process. Furthermore, the cell presents CTL epitopes of the polypeptide antigen bound to MHC Class I molecules on its surface. Cell-associated polypeptide antigens can therefore be truly intracellular antigens (and thereby unreachable for a humoral immune response) or antigens bound to the surface of the cells. The cell-associated polypeptide antigen can be the product of the cell's own gene expression, of an intracellular parasite, of a virus, or of another cell. In the latter case the polypeptide antigen is subsequently associated with the cell which is involved in the pathological process. Many of the polypeptide antigens against which the present invention is aimed, are cell-associated antigens. The term also includes within its scope a fragment of a protein, that is, the term "polypeptide antigen" denotes a continuous amino acid sequence found in a native protein.

The terms "T-lymphocyte" and "T-cell" will be used interchangeably for lymphocytes of thymic origin which are responsible for various cell mediated immune responses as well as for effector functions such as helper activity in the  
5 humoral immune response. Likewise, the terms "B-lymphocyte" and "B-cell" will be used interchangeably for antibody-producing lymphocytes.

An "antigen presenting cell" (APC) is a cell which presents epitopes to T-cells. Typical antigen-presenting cells are  
10 macrophages, dendritic cells and other phagocytizing and pinocytizing cells. It should be noted that B-cells also functions as APCs by presenting T<sub>H</sub> epitopes bound to MCH class II molecules to T<sub>H</sub> cells but when generally using the term APC in the present specification and claims it is intended to  
15 refer to the above-mentioned phagocytizing and pinocytizing cells.

"Helper T-lymphocytes" or "T<sub>H</sub> cells" denotes CD4 positive T-cells which provide help to B-cells and cytotoxic T-cells via the recognition of T<sub>H</sub> epitopes bound to MHC Class II molecules  
20 on antigen presenting cells.

The term "cytotoxic T-lymphocyte" (CTL) will be used for CD8 positive T-cells which require the assistance of T<sub>H</sub> cells in order to become activated.

A "specific" immune response is in the present context intended to denote a polyclonal immune response directed predominantly against a molecule or a group of quasi-identical molecules or, alternatively, against cells which present CTL epitopes of the molecule or the group of quasi-identical molecules.  
25

- A "weak or non-immunogenic polypeptide antigen" is herein intended to denote polypeptides having the amino acid sequence of the weak protein antigens derived from the animal in question (e.g. a human), but also polypeptides having the amino acid sequence identical to analogues of such proteins isolated from other species are embraced by the term. Also forms of the polypeptides having differing glycosylation patterns because of their production in heterologous systems (e.g. yeasts or other non-mammalian eukaryotic expression systems or even prokaryotic systems) are included within the boundaries of the term. It should, however, be noted that when using the term, it is intended that the polypeptide in question is normally non-immunogenic or only weakly immunogenic in its natural localisation in the animal to be treated.
- 15 The term "polypeptide" is in the present context intended to mean both short peptides of from 2 to 10 amino acid residues, oligopeptides of from 11 to 100 amino acid residues, and polypeptides of more than 100 amino acid residues. Furthermore, the term is also intended to include proteins, i.e. functional biomolecules comprising at least one polypeptide; when comprising at least two polypeptides, these may form complexes, be covalently linked, or may be non-covalently linked. The polypeptide(s) in a protein can be glycosylated and/or lipidated and/or comprise prosthetic groups.
- 25 The term "subsequence" means any consecutive stretch of at least 3 amino acids or, when relevant, of at least 3 nucleotides, derived directly from a naturally occurring amino acid sequence or nucleic acid sequence, respectively.

The term "animal" is in the present context in general intended to denote an animal species (preferably mammalian), such

as *Homo sapiens*, *Canis domesticus*, etc. and not just one single animal. However, the term also denotes a population of such an animal species, since it is important that the individuals immunized according to the method of the invention all  
5 harbour substantially the same weak polypeptide antigen allowing for immunization of the animals with the same immunogen(s). If, for instance, genetic variants of polypeptides exist in different human populations it may be necessary to use different immunogens in these different  
10 populations in order to be able to break the autotolerance towards the weak polypeptide antigen in each population.

By the term "down-regulation a polypeptide antigen" is herein meant reduction in the living organism of the amount and/or activity of the antigen in question. The down-regulation can  
15 be obtained by means of several mechanisms: Of these, simple interference with the active site in the antigen by antibody binding is the most simple. However, it is also within the scope of the present invention that the antibody binding results in removal of the polypeptide by scavenger cells (such  
20 as macrophages and other phagocytizing cells), and even more important, that cells carrying or harbouring the antigen are killed by CTLs in the animal.

The expression "effecting simultaneous presentation by a suitable APC" is intended to denote that the animal's immune  
25 system is subjected to an immunogenic challenge in a controlled manner which results in the simultaneous presentation by APCs of the epitopes in question. As will appear from the disclosure below, such challenge of the immune system can be effected in a number of ways of which the most important are  
30 vaccination with polypeptide containing "pharmaccines" (i.e. a vaccine which is administered to treat or ameliorate ongoing

disease) or nucleic acid "pharmaccine" vaccination. The important result to achieve is that immune competent cells in the animal are confronted with APCs displaying the relevant epitopes in an immunologically effective manner.

- 5 The term "immunogenically effective amount" has its usual meaning in the art, i.e. an amount of an immunogen which is capable of inducing an immune response which significantly engages pathogenic agents which share immunological features with the immunogen.
- 10 When using the expression that the weak polypeptide antigens have been subjected to a "modification" is herein meant a chemical modification of the polypeptide which constitutes the backbone of the polypeptide in question. Such a modification can e.g. be derivatization (e.g. alkylation) of certain amino
- 15 acid residues in the amino acid sequence, but as will be appreciated from the disclosure below, the preferred modifications comprise changes of the primary structure of the amino acid sequence.

- When discussing "tolerance" and "autotolerance" is understood
- 20 that since the polypeptides which are the targets of the present inventive method are self-proteins in the population to be vaccinated or proteins which do not result in induction of an effective immune response, normal individuals in the population do not mount an immune response against the
- 25 polypeptide. It cannot be excluded, though, that occasional individuals in an animal population might be able to produce antibodies against the native polypeptide antigen, e.g. as part of a autoimmune disorder. At any rate, an animal will normally only be autotolerant towards its own polypeptide
- 30 antigen, but it cannot be excluded that analogues derived from

other animal species or from a population having a different phenotype would also be tolerated by said animal.

A "foreign T-cell epitope" is a peptide which is able to bind to an MHC molecule and stimulates T-cells in an animal species. Preferred foreign epitopes are "promiscuous" epitopes (also known as universal epitopes), *i.e.* epitopes which binds to a substantial fraction of MHC class II molecules in an animal species or population. Only a very limited number of such promiscuous T-cell epitopes are known, and they will be discussed in detail below. It should be noted that in order for the immunogens which are used according to the present invention to be effective in as large a fraction of an animal population as possible, it may be necessary to 1) insert several foreign T-cell epitopes in the same analogue or 2) prepare several analogues wherein each analogue has a different promiscuous epitope inserted. It should be noted that the concept of foreign T-cell epitopes also encompasses use of cryptic T-cell epitopes, *i.e.* epitopes which are derived from a self-protein and which only exerts immunogenic behaviour when existing in isolated form without being part of the self-protein in question.

A "foreign T helper lymphocyte epitope" (a foreign  $T_H$  epitope) is a foreign T cell epitope which binds an MHC Class Class II molecule and can be presented on the surface of an antigen presenting cell (APC) bound to the MHC Class II molecule.

It follows logically from the above, that non-self proteins often by nature contain foreign  $T_H$  epitopes, and that introduction of other foreign epitopes may be unnecessary simply because polypeptide fragments of the non-self proteins

already include both the necessary CTL epitopes and the necessary foreign T<sub>H</sub> epitopes.

A "CTL" epitope is a peptide which is able to bind to an MHC class I molecule.

- 5 A "functional part" of a (bio)molecule is in the present context intended to mean the part of the molecule which is responsible for at least one of the biochemical or physiological effects exerted by the molecule. It is well-known in the art that many enzymes and other effector molecules have an  
10 active site which is responsible for the effects exerted by the molecule in question. Other parts of the molecule may serve a stabilizing or solubility enhancing purpose and can therefore be left out if these purposes are not of relevance in the context of a certain embodiment of the present inven-  
15 tion. For instance it is possible to use certain cytokines as a modifying moiety in the analogue (cf. the detailed discussion below), and in such a case, the issue of stability may be irrelevant since the coupling to the analogue provides the stability necessary.
- 20 The term "adjuvant" has its usual meaning in the art of vaccine technology, i.e. a substance or a composition of matter which is 1) not in itself capable of mounting a specific immune response against the immunogen of the vaccine, but which is 2) nevertheless capable of enhancing the immune  
25 response against the immunogen. Or, in other words, vaccination with the adjuvant alone does not provide an immune response against the immunogen, vaccination with the immunogen may or may not give rise to an immune response against the immunogen, but the combined vaccination with immunogen and

adjuvant induces an immune response against the immunogen which is stronger than that induced by the immunogen alone.

"Targeting" of a molecule is in the present context intended to denote the situation where a molecule upon introduction in the animal will appear preferentially in certain tissue(s) or will be preferentially associated with certain cells or cell types. The effect can be accomplished in a number of ways including formulation of the molecule in composition facilitating targeting or by introduction in the molecule of groups which facilitates targeting. These issues will be discussed in detail below.

"Stimulation of the immune system" means that a substance or composition of matter exhibits a general, non-specific immunostimulatory effect. A number of adjuvants and putative adjuvants (such as certain cytokines) share the ability to stimulate the immune system. The result of using an immunostimulating agent is an increased "alertness" of the immune system meaning that simultaneous or subsequent immunization with an immunogen induces a significantly more effective immune response compared to isolated use of the immunogen

#### Preferred embodiments

In order to induce a CTL response against a cell which presents epitopes derived from the polypeptide antigen on its surface, it is normally necessary that at least one CTL epitope, when presented, is associated with an MHC Class I molecule on the surface of the APC. Furthermore it is preferred that the at least one first foreign  $T_H$  epitope, when presented, is associated with an MHC Class II molecule on the surface of the APC.

Preferred APCs presenting the epitopes are dendritic cells and macrophages, but any pino- or phagocytizing APC which is capable of simultaneously presenting 1) CTL epitopes bound to MHC class I molecules and 2) T<sub>H</sub> epitopes bound to MHC class II molecules, is a preferred APC according to the invention.

According to the invention, the polypeptide antigen is preferably selected from a tumour-associated antigens and other self-proteins which are related to pathological processes but also viral antigens and antigens derived from an intracellular parasite or bacterium will. It is well-known in the art that such pathogen-associated antigens are often relatively poor immunogens (e.g. antigens from mycobacteria such as *Mycobacterium tuberculosis* and *Mycobacterium leprae*, but also from protozoans such as *Plasmodium spp.*). It is believed that the method of the invention, apart from rendering possible the production of antibody and CTL responses against true self-protein antigens, is capable of enhancing the often insufficient immune response mounted by the organism against such intracellular antigens. Hence, the method of the invention is not limited to induction of immune responses against self-proteins but also to induction of CTL responses against any antigen where this is desired. In this context it is important to note that the chitosan formulations described herein are also useful when combined with native polypeptide sequences (complete or truncated versions of those found in native proteins) as long as the native polypeptide sequence includes the T<sub>H</sub> epitopes necessary to induce an immune response against the native polypeptide.

Normally, it will be advantageous to confront the immune system with a large fraction of the amino acid sequence of the polypeptide antigen which is the vaccine target, i.a. by using

the polypeptide in its natural form. Hence, in a preferred embodiment, presentation by the APC of the CTL epitope and the first foreign T<sub>H</sub> epitope is effected by presenting the animal's immune system with at least one first analogue of the polypeptide antigen, said first analogue comprising a variation of the amino acid sequence of the polypeptide antigen, said variation containing at least the CTL epitope and the first foreign T<sub>H</sub> epitope. This is in contrast to e.g. a DNA vaccination strategy where the CTL and T<sub>H</sub> epitopes are expressed by the same cell but as parts of separate polypeptides; such a DNA vaccination strategy is also an embodiment of the invention, but it is believed that having the two epitopes as part of the same polypeptide will normally enhance the immune response and, at any rate, the provision of only one expression product will be necessary.

In order to maximize the chances of mounting an effective immune response, it is preferred that the above-mentioned first analogue contains a substantial fraction of known and predicted CTL epitopes of the polypeptide antigen, i.e. a fraction of the known and predicted CTL epitopes which binds a sufficient fractions of MHC Class I molecules in a population. For instance, it is preferred that the substantial fraction of known and predicted CTL epitopes in the amino acid sequence of the analogue are recognized by at least 50% of the MHC-I haplotypes recognizing all known and predicted CTL epitopes in the polypeptide antigen, but higher percentages are preferred, such as at least 60, at least 70, at least 80, and at least 90%. Especially preferred is the use of analogues which preserve substantially all known CTL epitopes of the polypeptide antigen are present in the analogue, i.e. close to 100% of the known CTL epitopes. Accordingly, it is also especially preferred that substantially all predicted CTL epitopes

of the polypeptide antigen are present in the at least first analogue.

Methods for predicting the presence of CTL epitopes are well-known in the art, cf. e.g. Rothbard et al. EMBO J. 7:93-100  
5 (1988).

As will be apparent from the present specification and claims it is expected that the inventive method described herein will render possible an improved induction of CTL responses against polypeptide antigens.

- 10 In cases where the polypeptide antigen is truly intracellular, the induction of a CTL response against cells harbouring the antigen is the only way to achieve its down-regulation by specific immunological means. However, in the case of membrane-associated antigens, it is advantageous to induce an  
15 antibody response against the weak polypeptide antigen. However, when raising a humoral immune response against a weak antigen it is preferred to substantially restrict the antibody response to interaction with the parts of the antigen which are normally exposed to possible interaction with antibodies.
- 20 Otherwise the result would most likely be the induction of an antibody response against parts of the antigen which is not normally engaging the humoral immune system, and this will in turn increase the risk of inducing cross-reactivity with antigens not related to any pathology. One elegant way of  
25 obtaining this restriction is to perform nucleic acid vaccination with an analogue of the weak antigen, where the extracellular part thereof is either unaltered or includes a  $T_H$  epitope which does not substantially alter the 3D structure of the extracellular part of the antigen. As one possible alter-  
30 native, immunization can be performed with both a CTL directed

immunogen and a B-cell directed immunogen where the B-cell directed immunogen is substantially incapable of effecting immunization against the intracellular part of the target antigen (the B-cell directed immunogen could e.g. lack any  
5 non-extracellular material from the antigen.

Induction of antibody responses can be achieved in a number of ways known to the person skilled in the art. For instance, the at least one first analogue may comprise a part consisting of a modification of the structure of the polypeptide antigen,  
10 said modification having as a result that immunization of the animal with the first analogue induces production of antibodies in the animal against the polypeptide antigen - this variant is as mentioned above especially suited for nucleic acid vaccination. Alternatively, the method of the  
15 invention can involve effecting presentation to the animal's immune system of an immunogenically effective amount of at least one *second* analogue of the polypeptide antigen which contains such a modification. A convenient way to achieve that the modification has the desired antibody-inducing effect is  
20 to include at least one second foreign  $T_H$  epitope in the second analogue, *i.e.* a strategy like the one used for the first analogue.

In the cases where it is desired to also mount an effective humoral immune response, it is advantageous that the first  
25 and/or second analogue(s) comprise(s) a substantial fraction of the polypeptide antigen's B-cell epitopes, especially a substantial fraction of such B-cell epitopes which are extracellular in the naturally occurring form of the antigen in the pertinent animal.

The above-discussed variations and modifications of the weak polypeptide antigen can take different forms. It is preferred that the variation and/or modification involves amino acid substitution and/or deletion and/or insertion and/or addition.

5 These fundamental operations relating to the manipulation of an amino acid sequence are intended to cover both single-amino acid changes as well as operations involving stretches of amino acids (*i.a.* shuffling of amino acid stretches within the polypeptide antigen; this is especially interesting when the

10 antigen is a true intracellular antigen, since only considerations concerning preservation of CTL epitopes are relevant). It will be understood, that the introduction of e.g. one single amino acid insertion or deletion may give rise to the emergence of a foreign  $T_H$  epitope in the sequence of the

15 analogue, *i.e.* the emergence of an MHC Class II molecule binding sequence. However, in most situations it is preferable (and even necessary) to introduce a known foreign  $T_H$  epitope, and such an operation will require amino acid substitution and/or insertion (or sometimes addition in the form of either

20 conjugation to a carrier protein or provision of a fusion polypeptide by means of molecular biology methods. It is preferred that the number of amino acid insertions, deletions, substitutions or additions is at least 2, such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 25

25 insertions, substitutions, additions or deletions. It is furthermore preferred that the number of amino acid substitutions is not in excess of 150, such as at most 100, at most 90, at most 80, and at most 70. It is especially preferred that the number of substitutions, insertions,

30 deletions, or additions does not exceed 60, and in particular the number should not exceed 50 or even 40. Most preferred is a number of not more than 30.

Preferred embodiments of the invention includes modification by introducing at least one foreign immunodominant T<sub>H</sub> epitope. It will be understood that the question of immune dominance of a T-cell epitope depends on the animal species in question. As  
5 used herein, the term "immunodominance" simply refers to epitopes which in the vaccinated individual/population gives rise to a significant immune response, but it is a well-known fact that a T-cell epitope which is immunodominant in one individual is not necessarily immunodominant in another indi-  
10 vidual of the same species, even though it may be capable of binding MHC-II molecules in the latter individual. True immune dominant T<sub>H</sub> epitopes are those which, independent of the polypeptide wherein they form a subsequence, give rise to activation of T<sub>H</sub> cells - in other words, some T<sub>H</sub> epitopes have,  
15 as an intrinsic feature, the characteristic of substantially never being cryptic since they are substantially always processed by APCs and presented in the context of an MHC II molecule on the surface of the APC.

Another important point is the issue of MHC restriction of T-  
20 cell epitopes. In general, naturally occurring T-cell epitopes are MHC restricted, i.e. a certain peptides constituting a T-cell epitope will only bind effectively to a subset of MHC Class II molecules. This in turn has the effect that in most cases the use of one specific T-cell epitope will result in a  
25 vaccine component which is only effective in a fraction of the population, and depending on the size of that fraction, it can be necessary to include more T-cell epitopes in the same molecule, or alternatively prepare a multi-component vaccine wherein the components are variants of the antigen which are  
30 distinguished from each other by the nature of the T-cell epitope introduced.

If the MHC restriction of the T-cells used is completely unknown (for instance in a situation where the vaccinated animal has a poorly defined MHC composition), the fraction of the population covered by a specific vaccine composition can  
5 be determined by means of the following formula

$$(II) \quad f_{\text{population}} = 1 - \prod_{i=1}^n (1 - p_i)$$

-where  $p_i$  is the frequency in the population of responders to the  $i^{\text{th}}$  foreign T-cell epitope present in the vaccine composition, and  $n$  is the total number of foreign T-cell epitopes in  
10 the vaccine composition. Thus, a vaccine composition containing 3 foreign T-cell epitopes having response frequencies in the population of 0.8, 0.7, and 0.6, respectively, would give

$$1 - 0.2 \times 0.3 \times 0.4 = 0.976$$

-i.e. 97.6 percent of the population will statistically mount  
15 an MHC-II mediated response to the vaccine.

The above formula does not apply in situations where a more or less precise MHC restriction pattern of the peptides used is known. If, for instance a certain peptide only binds the human MHC-II molecules encoded by HLA-DR alleles DR1, DR3, DR5, and  
20 DR7, then the use of this peptide together with another peptide which binds the remaining MHC-II molecules encoded by HLA-DR alleles will accomplish 100% coverage in the population in question. Likewise, if the second peptide only binds DR3 and DR5, the addition of this peptide will not increase the  
25 coverage at all. If one bases the calculation of population response purely on MHC restriction of T-cell epitopes in the vaccine, the fraction of the population covered by a specific vaccine composition can be determined by means of the following formula:

$$(III) f_{population} = 1 - \prod_{j=1}^3 (1 - \varphi_j)^2$$

-wherein  $\varphi_j$  is the sum of frequencies in the population of allelic haplotypes encoding MHC molecules which bind any one of the T-cell epitopes in the vaccine and which belong to the  $j^{th}$  of the 3 known HLA loci (DP, DR and DQ); in practice, it is first determined which MHC molecules will recognize each T-cell epitope in the vaccine and thereafter these are listed by type (DP, DR and DQ) - then, the individual frequencies of the different listed allelic haplotypes are summed for each type, thereby yielding  $\varphi_1$ ,  $\varphi_2$ , and  $\varphi_3$ .

It may occur that the value  $p_i$  in formula II exceeds the corresponding theoretical value  $\pi_i$ :

$$(IV) \quad \pi_i = 1 - \prod_{j=1}^3 (1 - \nu_j)^2$$

-wherein  $\nu_j$  is the sum of frequencies in the population of allelic haplotype encoding MHC molecules which bind the  $i^{th}$  T-cell epitope in the vaccine and which belong to the  $j^{th}$  of the 3 known HLA loci (DP, DR and DQ). This means that in  $1 - \pi_i$  of the population is a frequency of responders of  $f_{residual\_i} = (p_i - \pi_i) / (1 - \pi_i)$ . Therefore, formula III can be adjusted so as to yield formula V:

$$f_{population}^{(V)} = 1 - \prod_{j=1}^3 (1 - \varphi_j)^2 + \left( 1 - \prod_{i=1}^n (1 - f_{residual\_i}) \right)$$

-where the term  $1 - f_{residual\_i}$  is set to zero if negative. It should be noted that formula V requires that all epitopes have been haplotype mapped against identical sets of haplotypes.

Therefore, when selecting T-cell epitopes to be introduced in the analogue, it is important to include all knowledge of the epitopes which is available: 1) The frequency of responders in

the population to each epitope, 2) MHC restriction data, and 3) frequency in the population of the relevant haplotypes.

There exist a number of naturally occurring "promiscuous" T-cell epitopes which are active in a large proportion of individuals of an animal species or an animal population and these are preferably introduced in the vaccine thereby reducing the need for a very large number of different analogues in the same vaccine.

The promiscuous (universal) epitope can according to the invention be a naturally occurring human T-cell epitope such as epitopes from tetanus toxoid (e.g. the P2 and P30 epitopes that are disclosed as part of constructs in WO 00/20027), diphtheria toxoid, Influenza virus hemagglutinin (HA), and P. falciparum CS antigen.

Over the years a number of other promiscuous T-cell epitopes have been identified. Especially peptides capable of binding a large proportion of HLA-DR molecules encoded by the different HLA-DR alleles have been identified and these are all possible T-cell epitopes to be introduced in analogues used according to the present invention. Cf. also the epitopes discussed in the following references which are hereby all incorporated by reference herein: WO 98/23635 (Frazer IH et al., assigned to The University of Queensland); Southwood S et al., 1998, J. Immunol. **160**: 3363-3373; Sinigaglia F et al., 1988, Nature **336**: 778-780; Rammensee HG et al., 1995, Immunogenetics **41**: 4178-228; Chicz RM et al., 1993, J. Exp. Med **178**: 27-47; Hammer J et al., 1993, Cell **74**: 197-203; and Falk K et al., 1994, Immunogenetics **39**: 230-242. The latter reference also deals with HLA-DQ and -DP ligands. All epitopes listed in these 5 references are relevant as candidate natural epitopes to be

used in the present invention, as are epitopes which share common motifs with these.

Alternatively, the epitope can be any artificial T-cell epitope which is capable of binding a large proportion of haplo-  
5 types. In this context the pan DR epitope peptides ("PADRE") described in WO 95/07707 and in the corresponding paper Alexander J et al., 1994, Immunity 1: 751-761 (both disclosures are incorporated by reference herein) are interesting candidates for epitopes to be used according to the present inven-  
10 tion. It should be noted that the most effective PADRE peptides disclosed in these papers carry D-amino acids in the C- and N-termini in order to improve stability when administered. However, the present invention primarily aims at incorporating the relevant epitopes as part of the modified antigen which  
15 should then subsequently be broken down enzymatically inside the lysosomal compartment of APCs to allow subsequent presentation in the context of an MHC-II molecule and therefore it is not expedient to incorporate D-amino acids in the epitopes used in the present invention.

20 One especially preferred PADRE peptide is the one having the amino acid sequence AKFVAAWTLKAAA or an immunologically effective subsequence thereof. This, and other epitopes having the same lack of MHC restriction are preferred T-cell epitopes which should be present in the analogues used in the inventive  
25 method. Such super-promiscuous epitopes will allow for the most simple embodiments of the invention wherein only one single analogue is presented to the vaccinated animal's immune system.

The nature of the above-discussed variation/modification  
30 preferably comprises that

- at least one first moiety is included in the first and/or second analogue(s), said first moiety effecting targeting of the analogue to an antigen presenting cell (APC), and/or
  - at least one second moiety is included in the first and/or  
5 second analogue(s), said second moiety stimulating the immune system, and/or
  - at least one third moiety is included in the first and/or second analogue(s), said third moiety optimizing presentation of the analogue to the immune system.
- 10 The functional and structural features relating these first, second and third moieties will be discussed in the following:
- They can be present in the form of side groups attached covalently or non-covalently to suitable chemical groups in the amino acid sequence of the polypeptide antigen or a  
15 subsequence thereof. This is to mean that stretches of amino acid residues derived from the polypeptide antigen are derivatized without altering the primary amino acid sequence, or at least without introducing changes in the peptide bonds between the individual amino acids in the chain.
- 20 The moieties can also be in the form of fusion partners to the amino acid sequence derived from the polypeptide antigen. In this connection it should be mentioned that both possibilities include the option of conjugating the amino acid sequence to a carrier, cf. the discussion of these below. In other words, in  
25 the present context the term "fusion protein is not merely restricted to a fusion construct prepared by means of expression of a DNA fragment encoding the construct but also to a conjugate between two proteins which are joined by means of a peptide bond in a subsequent chemical reaction.

As mentioned above, the analogue can also include the introduction of a first moiety which targets the analogue to an APC or a B-lymphocyte. For instance, the first moiety can be a specific binding partner for a B-lymphocyte specific surface antigen or for an APC specific surface antigen. Many such specific surface antigens are known in the art. For instance, the moiety can be a carbohydrate for which there is a receptor on the B-lymphocyte or the APC (e.g. mannan or mannose). Alternatively, the second moiety can be a hapten. Also an antibody fragment which specifically recognizes a surface molecule on APCs or lymphocytes can be used as a first moiety (the surface molecule can e.g. be an FC $\gamma$  receptor of macrophages and monocytes, such as FC $\gamma$ RI or, alternatively any other specific surface marker such as CD40 or CTLA-4). It should be noted that all these exemplary targeting molecules can be used as part of an adjuvant, cf. below. CD40 ligand, antibodies against CD40, or variants thereof which bind CD40 will target the analogue to dendritic cells. At the same time, recent results have shown that the interaction with the CD40 molecule renders the T<sub>H</sub> cells unessential for obtaining a CTL response. Hence, it is contemplated that the general use of CD40 binding molecules as the first moiety (or as adjuvants, cf. below) will enhance the CTL response considerably; in fact, the use of such CD40 binding molecules as adjuvants and "first moieties" in the meaning of the present invention is believed to be inventive in its own right.

As an alternative or supplement to targeting the analogue to a certain cell type in order to achieve an enhanced immune response, it is possible to increase the level of responsiveness of the immune system by including the above-mentioned second moiety which stimulates the immune system. Typical

examples of such second moieties are cytokines, heat-shock proteins, and hormones, as well as effective parts thereof.

Suitable cytokines to be used according to the invention are those which will normally also function as adjuvants in a vaccine composition, e.g. interferon  $\gamma$  (IFN- $\gamma$ ), Flt3 ligand (Flt3L), interleukin 1 (IL-1), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 12 (IL-12), interleukin 13 (IL-13), interleukin 15 (IL-15), and granulocyte-macrophage colony stimulating factor (GM-CSF); alternatively, the functional part of the cytokine molecule may suffice as the second moiety. With respect to the use of such cytokines as adjuvant substances, cf. the discussion below.

Alternatively, the second moiety can be a toxin, such as listeriolysin (LLO), lipid A and heat-labile enterotoxin. Also, a number of mycobacterial derivatives such as MDP (muramyl dipeptide), CFA (complete Freund's adjuvant) and the trehalose diesters TDM and TDE are interesting possibilities.

According to the invention, suitable heat shock proteins used as the second moiety can be HSP70, HSP90, HSC70, GRP94, and calreticulin (CRT).

Also the possibility of introducing a third moiety which enhances the presentation of the analogue to the immune system is an important embodiment of the invention. The art has shown several examples of this principle. For instance, it is known that the palmitoyl lipidation anchor in the *Borrelia burgdorferi* protein OspA can be utilised so as to provide self-  
adjuvating polypeptides (cf. e.g. WO 96/40718). It seems that the lipidated proteins form up micelle-like structures with a

core consisting of the lipidation anchor parts of the polypeptides and the remaining parts of the molecule protruding therefrom, resulting in multiple presentations of the antigenic determinants. Hence, the use of this and related approaches using different lipidation anchors (e.g. a myristyl group, a farnesyl group, a geranyl-geranyl group, a GPI-anchor, and an N-acyl diglyceride group) are preferred embodiments of the invention, especially since the provision of such a lipidation anchor in a recombinantly produced protein is fairly straightforward and merely requires use of e.g. a naturally occurring signal sequence as a fusion partner for the analogue. Another possibility is use of the C3d fragment of complement factor C3 or C3 itself (cf. Dempsey et al., 1996, Science 271, 348-350 and Lou & Kohler, 1998, Nature Biotechnology 16, 458-462).

It is important to note that when attempting to use the method of the invention against e.g. membrane bound polypeptide antigens which are exposed to the extracellular compartment, it is most preferred that the first and/or second analogue(s) has/have substantially the overall tertiary structure of the polypeptide antigen. In the present specification and claims this is intended to mean that the overall tertiary structure of the part of the polypeptide antigen which is extracellularly exposed is preserved, since, as mentioned above, the tertiary structure of the obligate intracellular polypeptides do not engage the humeral immune system. In fact, as part of the vaccination strategy it is often desired to avoid exposure to the extracellular compartment of putative B-cell epitopes derived from intracellular part of the polypeptide antigens; in this way, potentially adverse effects caused by cross-reactivity with other antigens can be minimized.

For the purposes of the present invention, it is however sufficient if the variation/modification (be it an insertion, addition, deletion or substitution) gives rise to a foreign T-cell epitope and at the same time preserves a substantial  
 5 number of the CTL epitopes in the polypeptide antigen (and sometimes also a substantial number of B-cell epitopes).

The following formula describes the constructs generally covered by the invention:

$$(\text{MOD}_1)_{s1} (\text{PAG}_{e1})_{n1} (\text{MOD}_2)_{s2} (\text{PAG}_{e2})_{n2} \dots (\text{MOD}_x)_{sx} (\text{PAG}_{ex})_{nx} \quad (\text{I})$$

10 -where  $\text{PAG}_{e1}$ - $\text{PAG}_{ex}$  are  $x$  CTL and/or B-Cell epitope containing subsequences of the relevant polypeptide antigen which independently are identical or non-identical and which may contain or not contain foreign side groups,  $x$  is an integer  $\geq 3$ ,  $n1$ - $n_x$  are  $x$  integers  $\geq 0$  (at least one is  $\geq 1$ ),  $\text{MOD}_1$ - $\text{MOD}_x$  are  $x$   
 15 modifications introduced between the preserved epitopes, and  $s1$ - $s_x$  are  $x$  integers  $\geq 0$  (at least one is  $\geq 1$  if no side groups are introduced in the sequences). Thus, given the general functional restraints on the immunogenicity of the constructs, the invention allows for all kinds of permutations of the  
 20 original antigen sequence, and all kinds of modifications therein. Thus, included in the invention are analogues obtained by omission of parts of the polypeptide antigen sequence which e.g. exhibit adverse effects in vivo or omission of parts which are normally intracellular and thus could  
 25 give rise to undesired immunological reactions, cf. the detailed discussion below.

A further elaboration of the above principle include use of CTL and/or B-cell epitopes from more than one pathology-related antigen. For instance, there are several cancer related

antigens that exert their oncogenic effects when they are in a mutated form only - examples are mutated K-ras and P53 which both are crucial proteins in normal cell cycle regulation and which both are expression products in most normal cells. In some cases, CTLs have been shown to recognise mutated peptides from these antigens. It is therefore important that the immune system responds to the mutated peptide only, and not to the unmutated parts, if antigen specific immunotherapy is instigated.

10 We have devised a strategy whereby sequences of 8-25 amino acids of such disease-related proteins could be used as further epitopes in an AutoVac construct - in preferred embodiments, the introduced epitopes would at the same time provide for the emergence of  $T_H$  epitopes in the final construct, cf.

15 the discussion above. The epitopes used for this purpose would be those which comprise the mutated region of the disease-related protein. By using such an approach, it would be possible to generate CTLs (and possibly antibodies, where applicable) against only the mutated form of the disease-related

20 antigen. In the cases where the disease-related antigen provides for the emergence of a  $T_H$  epitope, the use of a truly foreign  $T_H$  epitope could be completely omitted. An embodiment of this principle could e.g. be vaccination with a nucleic acid vaccine which encode an analogue of a polypeptide antigen

25 (e.g. Her2 or PSM) wherein has been introduced at least one  $T_H$  epitope and at least one peptide derived from another disease-related antigen (e.g. a peptide from the mutated part of an oncogenic protein). In a preferred embodiment, the at least one  $T_H$  epitope is introduced as a consequence of the introduction of the peptide.

30

It is furthermore preferred that the variation and/or modification includes duplication, when applicable, of the at least one B-cell epitope, or of at least one CTL epitope of the polypeptide antigen. This strategy will give the result that  
5 multiple copies of preferred epitopic regions are presented to the immune system and thus maximizing the probability of an effective immune response. Hence, this embodiment of the invention utilises multiple presentations of epitopes derived from the polypeptide antigen (*i.e.* formula I wherein at least  
10 one B-cell epitope is present in two positions).

This effect can be achieved in various ways, *e.g.* by simply preparing fusion polypeptides comprising the structure  $(PAG)_m$ , where  $m$  is an integer  $\geq 2$  and then introduce the modifications discussed herein in at least one of the polypeptide antigen  
15 sequences.

An alternative embodiment of the invention which also results in the preferred presentation of multiple (*e.g.* at least 2) copies of the important epitopic regions of the antigen to the immune system is the covalent coupling of the antigen, subse-  
20 quence or variants thereof to certain molecules. For instance, polymers can be used, *e.g.* carbohydrates such as dextran, *cf.* *e.g.* Lees A et al., 1994, Vaccine 12: 1160-1166; Lees A et al., 1990, J Immunol. 145: 3594-3600, but also mannose and mannan are useful alternatives. Integral membrane proteins  
25 from *e.g.* *E. coli* and other bacteria are also useful conjugation partners. The traditional carrier molecules such as keyhole limpet haemocyanin (KLH), tetanus toxoid, diphtheria toxoid, and bovine serum albumin (BSA) are also preferred and useful conjugation partners.

Maintenance of the sometimes advantageous substantial fraction of B-cell epitopes or even the overall tertiary structure of a protein which is subjected to modification as described herein can be achieved in several ways. One is simply to prepare a polyclonal antiserum directed against the polypeptide antigen (e.g. an antiserum prepared in a rabbit) and thereafter use this antiserum as a test reagent (e.g. in a competitive ELISA) against the modified proteins which are produced. Modified versions (analogues) which react to the same extent with the antiserum as does the polypeptide antigen must be regarded as having the same overall tertiary structure as the polypeptide antigen whereas analogues exhibiting a limited (but still significant and specific) reactivity with such an antiserum are regarded as having maintained a substantial fraction of the original B-cell epitopes.

Alternatively, a selection of monoclonal antibodies reactive with distinct epitopes on the polypeptide antigen can be prepared and used as a test panel. This approach has the advantage of allowing 1) an epitope mapping of the polypeptide antigen in question and 2) a mapping of the epitopes which are maintained in the analogues prepared.

Of course, a third approach would be to resolve the 3-dimensional structure of the polypeptide antigen or of a biologically active truncate thereof (cf. above) and compare this to the resolved three-dimensional structure of the analogues prepared. Three-dimensional structure can be resolved by the aid of X-ray diffraction studies and NMR-spectroscopy. Further information relating to the tertiary structure can to some extent be obtained from circular dichroism studies which have the advantage of merely requiring the polypeptide in pure form (whereas X-ray diffraction requires the provision of crystal-

lized polypeptide and NMR requires the provision of isotopic variants of the polypeptide) in order to provide useful information about the tertiary structure of a given molecule.

However, ultimately X-ray diffraction and/or NMR are necessary  
5 to obtain conclusive data since circular dichroism can only provide indirect evidence of correct 3-dimensional structure via information of secondary structure elements.

For the purposes of the present invention it should also be mentioned that instead of using naturally occurring B and CTL  
10 epitopes, it is possible to use mimotopes which are isolated from e.g. phage libraries which are tested against antibodies which are known to bind to the relevant antigen.

In essence there are at present three feasible ways of obtaining the presentation of the relevant epitopes to the immune  
15 system: Traditional sub-unit vaccination with polypeptide antigens, administration of a genetically modified live vaccine, and nucleic acid vaccination. These three possibilities will be discussed separately in the following:

#### Polypeptide vaccination

20 This entails administration to the animal in question of an immunogenically effective amount of the polypeptide antigen or the variant thereof, and, when relevant, administration of an immunologically effective amount of the at least one second analogue.

25 The chitosan formulation of polypeptides can be accomplished in a number of ways. Simple admixture of chitosan and polypeptide is one way, but in preferred embodiments of the invention, the polypeptide is part of a chitosan microparticle (i.e. a bead, microsphere or microcapsule). Methods for

preparing and loading such microparticles are well-known in the art, cf. e.g. Kas HS, 1997, J. Microencapsulation 14(6), 689-711.

The mean molecular weight of the chitosan is of importance for the size of the microparticles produced but may also have implications for the immunogenic properties of simple admixtures of chitosan and polypeptide antigen. Generally, the chitosan should have a mean molecular weight in the range from about 3,000 to about 3,000,000, where the preferred molecular weight is in the range from about 30,000 to about 2,000,000. Especially preferred are molecular weights in the range from about 50,000 to about 500,000, and more preferred are molecular weights in the range from about 60,000 to about 400,000. Still more preferred are molecular weights in the range from about 70,000 to about 300,000 and even more preferred are molecular weights in the range from about 80,000 to about 200,000. Most preferred are molecular weights in the range from about 90,000 to about 150,000, notably molecular weights ranging from about 95,000 to about 130,000.

Also the viscosity of the chitosan molecules, as measured for 1% chitosan in 1% acetic acid, are of importance. Generally, viscosities will preferably range from about 2 mPas to about 500 mPas, with preferred viscosities in the range from about 3 to about 300 mPas. Especially preferred are viscosities in the range from about 4 to about 200 mPas, and even more preferred are viscosities in the range from about 5 to about 150 mPas. Yet more preferred are viscosities in the range from about 6 to about 120 mPas, with especially preferred viscosities in the range from about 7 to about 100 mPas. Most preferred are viscosities in the range from about 8 to about 80 mPas with very useful viscosities in the range from about 9 to about 60

mPas. Especially good results and particle sizes are obtained when using chitosan viscosities in the range from about 10 to about 40 mPas, where viscosities in the range from about 11 to about 20 mPas are most preferred. The examples given herein  
5 have utilised chitosan with a viscosity of about 12 mPas.

A third characteristic of the chitosan molecules which is of importance is their degree of acetylation (measured as the percentage of acetyl groups in the chitosan molecule relative to the maximum possible number of acetyl groups of a  
10 corresponding chitin molecule) - normally, this characteristic is expressed as the degree of deacetylation, i.e. 100% minus the percentage of acetylation. The degree of deacetylation is of importance because it e.g. determines the net charge of the chitosan particles prior to loading with antigen.

15 In general, the degrees of deacetylation of the chitosan molecules are those of at least about 65%, but in general it is preferred that the degree of deacetylation is as high as possible. Therefore, it is preferred that the deacetylation degree is at least 70%, such as at least 75%, but even higher  
20 degrees of deacetylation are preferred such as at least 80% or higher, e.g. at least 85%. Most preferred are degrees of deacetylation of at least 87%, more preferred at least 89% and even more preferred at least 91%. Very good results are expected if using chitosan having a degree of deacetylation of  
25 at least 93%, such as at least 95%, or even at least 97%. As shown in the examples, the use of chitosan with a deacetylation degree of more than 98% have proven very effective, and this is thus the most preferred embodiment.

The mean diameter of chitosan microparticles should be in the  
30 range between 0.1 and 10  $\mu\text{m}$ , preferably between 0.2 and 5  $\mu\text{m}$ ,

more preferred between 0.3 and 2.5  $\mu\text{m}$ , especially in the range between 0.4 and 2  $\mu\text{m}$ , and most preferred between 0.5 and 1.5  $\mu\text{m}$ . Very good results are expected when the particle diameter is between 0.6 and 1.3  $\mu\text{m}$ , such as between 0.65 and 1.2  $\mu\text{m}$ ,  
5 especially between 0.7 and 1.0  $\mu\text{m}$ . Most preferred, the particle diameter should be in the range between 0.73 and 0.82  $\mu\text{m}$ .

Finally, the mean  $\zeta$  (zeta) potential of the unloaded microparticles should in general be in the range from about  
10 +0.5 to about +50 mV, with preferred mean  $\zeta$  potentials in the upper part of this range. Thus, preferred mean  $\zeta$  potentials range from about 15 to about 45 mV, with more preferred mean  $\zeta$  potentials in the range from about 20 to about 42 mV. Most preferred are mean  $\zeta$  potentials in the range between 25 and 41  
15 mV, such as between 30 and 40 mV, and more precisely in the range between 33 and 39 mV, such as between 34 and 38 mV.

It has proven effective to stabilise the chitosan particles characterized above by subsequent cross-linking. The cross-linking may be performed by any suitable method known in the  
20 art, i.e. by means of cross-linking agents such as glutaraldehyde and formaldehyde or by means of gelling agents such as alginate. The cross-linking of the chitosan particles may be performed both prior to loading with immunogen or after, according to the methods known in the art referred to  
25 in the following.

In general, the polypeptide antigen or variant thereof is included in the particles by means of passive absorption or any other suitable method of incorporation so as to obtain loaded particles with a suitable ratio between chitosan and  
30 polypeptide. This ratio should normally be in the range

between 10 and 1 (measured as g chitosan per g polypeptide), with preferred ratios in the range between 8 and 1.3, such as the range between 5 and 1.5. Most preferred are ratios between 3 and 1.7, such as ratios between 2.5 and 1.8. It is most  
5 preferred that the ratio is about 2.

It is believed that the inclusion of minor amounts of detergent in the chitosan formulation will enhance the CTL induction mediated by immunogenic composition. Without being limited to any theory, it is nevertheless believed that the  
10 chitosan facilitate pinocytotic uptake by APCs of the polypeptide antigen or the variant thereof. After entry into the endosomal compartment the chitosan is degraded, and the detergent may thereafter facilitate the release of the polypeptide from the endosomes.

15 It will be clear for the skilled artisan that the amount and activity of the detergent must be adjusted carefully so as to on the one hand facilitate CTL responses while on the other hand avoiding toxic side effects exerted on the APC. Or, in other words, the amount of detergent must be effective but on  
20 the other hand pharmaceutically acceptable.

The detergent can be any one of the adjuvants described herein which are at the same time detergents, cf. below. Very good candidates are QuilA, listeriolysin, Tween 20, and Tween 80, but the choice of detergent is not critical.

25 The amount of detergent will have to be determined, depending on the precise choice thereof. The easiest way to determine a useful amount is to admix chitosan or to load microparticles with varying amounts of detergent and immunogenic polypeptide, and thereafter determine the detergent concentration which

results in the highest degree of the desired immunologic reactivity.

It should be noted that since the presently used method for preparation of microparticles entail the use of the detergent Tween 80, it is believed that residual amounts of this detergent may be responsible for the high CTL induction and specific T-cell proliferation seen after administration to mice.

As an alternative to formulations of polypeptide antigen or variant thereof in chitosan, one may advantageously couple the polypeptide antigens or variants of the immunogenic composition covalently to chitosan, e.g. by standard methods for chemical conjugation of molecules.

Preferably, the polypeptide antigen or variant thereof (e.g. the at least one first and/or second analogue(s)) is/are further formulated together with a pharmaceutically and immunologically acceptable carrier and/or vehicle and, optionally an adjuvant.

When effecting presentation of the analogue to an animal's immune system by means of administration thereof to the animal, the formulation of the polypeptide follows the principles generally acknowledged in the art.

Preparation of vaccines which contain peptide sequences as active ingredients is generally well understood in the art, as exemplified by US Patents 4,608,251; 4,601,903; 4,599,231; 4,599,230; 4,596,792; and 4,578,770, all incorporated herein by reference. Typically, such vaccines are prepared as injectables either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to

injection may also be prepared. The preparation may also be emulsified. The active immunogenic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients  
5 are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or adjuvants which enhance the effectiveness of the  
10 vaccines; cf. the detailed discussion of adjuvants below.

The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously, intradermally, subdermally or intramuscularly. Additional formulations which are suitable for other modes of administration include suppos-  
15 itories and, in some cases, oral, buccal, sublingual, intraperitoneal, intravaginal, anal and intracranial formulations. For suppositories, traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the  
20 active ingredient in the range of 0.5% to 10%, preferably 1-2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions  
25 take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10-95% of active ingredient, preferably 25-70%. For oral formulations, cholera toxin is an interesting formulation partner (and also a possible conjugation partner).

30 The polypeptides may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include acid

addition salts (formed with the free amino groups of the peptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like.

- 5 Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
- 10 The vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective and immunogenic. The quantity to be administered depends on the subject to be treated, including, e.g., the capacity of the individual's immune system to mount an
- 15 immune response, and the degree of protection desired. Suitable dosage ranges are of the order of several hundred micrograms active ingredient per vaccination with a preferred range from about 0.1  $\mu\text{g}$  to 2000  $\mu\text{g}$  (even though higher amounts in the 1-10 mg range are contemplated), such as in the range from
- 20 about 0.5  $\mu\text{g}$  to 1000  $\mu\text{g}$ , preferably in the range from 1  $\mu\text{g}$  to 500  $\mu\text{g}$  and especially in the range from about 10  $\mu\text{g}$  to 100  $\mu\text{g}$ . Suitable regimens for initial administration and booster shots are also variable but are typified by an initial administration followed by subsequent inoculations or other adminis-
- 25 tions.

The manner of application may be varied widely. Any of the conventional methods for administration of a vaccine are applicable. These include oral application on a solid physiologically acceptable base or in a physiologically acceptable

30 dispersion, parenterally, by injection or the like. The dosage of the vaccine will depend on the route of administration and

will vary according to the age of the person to be vaccinated and the formulation of the antigen.

Some of the polypeptides of the vaccine are sufficiently immunogenic in a vaccine, but for some of the others the  
5 immune response will be enhanced if the vaccine further comprises an adjuvant substance. It is especially preferred to use an adjuvant which can be demonstrated to facilitate breaking of the autotolerance to autoantigens.

Various methods of achieving adjuvant effect for the vaccine  
10 are known. General principles and methods are detailed in "The Theory and Practical Application of Adjuvants", 1995, Duncan E.S. Stewart-Tull (ed.), John Wiley & Sons Ltd, ISBN 0-471-95170-6, and also in "Vaccines: New Generation Immunological Adjuvants", 1995, Gregoriadis G et al. (eds.), Plenum Press,  
15 New York, ISBN 0-306-45283-9, both of which are hereby incorporated by reference herein.

Preferred adjuvants facilitate uptake of the vaccine molecules by APCs, such as dendritic cells, and activate these. Non-limiting examples are selected from the group consisting of an  
20 immune targeting adjuvant; an immune modulating adjuvant such as a toxin, a cytokine, and a mycobacterial derivative; an oil formulation; a polymer; a micelle forming adjuvant; a saponin; an immunostimulating complex matrix (ISCOM matrix); a particle; DDA; aluminium adjuvants; DNA adjuvants;  $\gamma$ -inulin; and  
25 an encapsulating adjuvant. In general it should be noted that the disclosures above which relate to compounds and agents useful as first, second and third moieties in the analogues also refer *mutatis mutandis* to their use in the adjuvant of a vaccine of the invention.

The application of adjuvants include use of agents such as aluminum hydroxide or phosphate (alum), commonly used as 0.05 to 0.1 percent solution in buffered saline, admixture with synthetic polymers of sugars (e.g. Carbopol®) used as 0.25 percent solution, aggregation of the protein in the vaccine by heat treatment with temperatures ranging between 70° to 101°C for 30 second to 2 minute periods respectively and also aggregation by means of cross-linking agents are possible. Aggregation by reactivation with pepsin treated antibodies (Fab fragments) to albumin, mixture with bacterial cells such as *C. parvum* or endotoxins or lipopolysaccharide components of gram-negative bacteria, emulsion in physiologically acceptable oil vehicles such as mannide mono-oleate (Aracel A) or emulsion with 20 percent solution of a perfluorocarbon (Fluosol-DA) used as a block substitute may also be employed. Admixture with oils such as squalene and IFA is also preferred.

According to the invention DDA (dimethyldioctadecylammonium bromide) is an interesting candidate for an adjuvant as is DNA and  $\gamma$ -inulin, but also Freund's complete and incomplete adjuvants as well as quillaja saponins such as QuilA and QS21 are interesting. Further possibilities are monophosphoryl lipid A (MPL), and the above mentioned C3 and C3d.

Liposome formulations are also known to confer adjuvant effects, and therefore liposome adjuvants are preferred according to the invention.

Also immunostimulating complex matrix type (ISCOM® matrix) adjuvants are preferred choices according to the invention, especially since it has been shown that this type of adjuvants are capable of up-regulating MHC Class II expression by APCs. An ISCOM® matrix consists of (optionally fractionated) sapo-

nins (triterpenoids) from *Quillaja saponaria*, cholesterol, and phospholipid. When admixed with the immunogenic protein, the resulting particulate formulation is what is known as an ISCOM particle where the saponin constitutes 60-70% w/w, the cholesterol and phospholipid 10-15% w/w, and the protein 10-15% w/w. Details relating to composition and use of immunostimulating complexes can e.g. be found in the above-mentioned text-books dealing with adjuvants, but also Morein B et al., 1995, Clin. Immunother. 3: 461-475 as well as Barr IG and Mitchell GF, 10 1996, Immunol. and Cell Biol. 74: 8-25 (both incorporated by reference herein) provide useful instructions for the preparation of complete immunostimulating complexes.

Another highly interesting (and thus, preferred) possibility of achieving adjuvant effect is to employ the technique described in Gosselin et al., 1992, J. Immunol 149(11): 3477-81 (which is hereby incorporated by reference herein). In brief, the presentation of a relevant antigen such as an antigen of the present invention can be enhanced by conjugating the antigen to antibodies (or antigen binding antibody fragments) 20 against the Fcγ receptors on monocytes/macrophages. Especially conjugates between antigen and anti-FcγRI have been demonstrated to enhance immunogenicity for the purposes of vaccination.

Other possibilities involve the use of the targeting and 25 immune modulating substances (i.a. cytokines) mentioned above as candidates for the first and second moieties in the modified analogues. In this connection, also synthetic inducers of cytokines like poly I:C are possibilities.

Suitable mycobacterial derivatives are selected from the group consisting of muramyl dipeptide, complete Freund's adjuvant, RIBI, and a diester of trehalose such as TDM and TDE.

Suitable immune targeting adjuvants are selected from the  
5 group consisting of CD40 ligand and CD40 antibodies or specifically binding fragments thereof (cf. the discussion above), mannose, a Fab fragment, and CTLA-4.

Suitable polymer adjuvants are selected from the group consisting of a carbohydrate such as dextran, PEG, starch, man-  
10 nan, and mannose; a plastic polymer; and latex such as latex beads.

Yet another interesting way of modulating an immune response is to include the immunogen (optionally together with adjuvants and pharmaceutically acceptable carriers and vehicles)  
15 in a "virtual lymph node" (VLN) (a proprietary medical device developed by ImmunoTherapy, Inc., 360 Lexington Avenue, New York, NY 10017-6501). The VLN (a thin tubular device) mimics the structure and function of a lymph node. Insertion of a VLN under the skin creates a site of sterile inflammation with an  
20 upsurge of cytokines and chemokines. T- and B-cells as well as APCs rapidly respond to the danger signals, home to the inflamed site and accumulate inside the porous matrix of the VLN. It has been shown that the necessary antigen dose required to mount an immune response to an antigen is reduced  
25 when using the VLN and that immune protection conferred by vaccination using a VLN surpassed conventional immunization using Ribi as an adjuvant. The technology is *i.a.* described briefly in Gelber C et al., 1998, "Elicitation of Robust Cellular and Humoral Immune Responses to Small Amounts of  
30 Immunogens Using a Novel Medical Device Designated the Virtual

Lymph Node", in: "From the Laboratory to the Clinic, Book of Abstracts, October 12<sup>th</sup> - 15<sup>th</sup> 1998, Seascape Resort, Aptos, California".

Recent findings have demonstrated that the co-administration  
5 of H2 agonists enhances the in-tumour survival of Natural Killer Cells and CTLs. Hence, it is also contemplated to include H2 agonists as adjuvants in the methods of the invention.

It is expected that the vaccine should be administered at  
10 least once a year, such as at least 1, 2, 3, 4, 5, 6, and 12 times a year. More specifically, 1-12 times per year is expected, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 times a year to an individual in need thereof. It has previously been shown that the memory immunity induced by the use of the  
15 preferred autovaccines according to the invention is not permanent, and therefor the immune system needs to be periodically challenged with the analogues.

It should be noted that vaccination with peptides/polypeptides according to the present invention may be the second step  
20 ("primary boost") which follows after nucleic acid vaccination. Extremely promising results have been obtained using such an immunization strategy with Her2 antigen variants described herein, even without using chitosan in the formulation but by otherwise following the teaching of the  
25 present invention.

Due to genetic variation, different individuals may react with immune responses of varying strength to the same polypeptide. Therefore, the vaccine according to the invention may comprise several different polypeptides in order to increase the immune  
30 response, cf. also the discussion above concerning the choice

of foreign T-cell epitope introductions. The vaccine may comprise two or more polypeptides, where all of the polypeptides are as defined above.

The vaccine may consequently comprise 3-20 different modified  
5 or unmodified polypeptides, such as 3-10 different polypeptides. However, normally the number of peptides will be sought kept to a minimum such as 1 or 2 peptides. Nucleic acid vaccination

As an alternative to classic administration of a peptide-based  
10 vaccine, the technology of nucleic acid vaccination (also known as "nucleic acid immunisation", "genetic immunisation", "gene immunisation" and "DNA vaccination") offers a number of attractive features. Hence, although the main focus of the present invention is polypeptide vaccination, it is believed  
15 that certain of the present chitosan formulations described above may prove superior to existing nucleic acid vaccine formulations.

First, in contrast to the traditional vaccine approach, nucleic acid vaccination does not require resource consuming  
20 large-scale production of the immunogenic agent (e.g. in the form of industrial scale fermentation of microorganisms producing the wild-type polypeptides or the analogues necessary in polypeptide vaccination). Furthermore, there is no need to device purification and refolding schemes for the immunogen.  
25 And finally, since nucleic acid vaccination relies on the biochemical apparatus of the vaccinated individual in order to produce the expression product of the nucleic acid introduced, the optimum posttranslational processing of the expression product is expected to occur; this is especially important in  
30 the case of autovaccination, since, as mentioned above, a

significant fraction of the original B-cell epitopes should be preserved in the analogues derived from extracellularly exposed polypeptide sequences, and since B-cell epitopes in principle can be constituted by parts of any (bio)molecule  
5 (e.g. carbohydrate, lipid, protein etc.). Therefore, native glycosylation and lipidation patterns of the immunogen may very well be of importance for the overall immunogenicity and this is best ensured by having the host producing the immunogen.

10 Hence, an important embodiment of the method of the invention involves that presentation is effected by *in vivo* introducing, into the APC, at least one nucleic acid fragment which encodes and expresses the at least one CTL epitope and/or the at least one B-cell epitope, and the at least one first foreign T<sub>H</sub>  
15 epitope (an alternative encompasses administration of at least 2 distinct nucleic acid fragments, where one encodes the at least one CTL epitope and the other encodes the at least one foreign T<sub>H</sub> epitope). Preferably, this is done by using a nucleic acid fragment which encodes and expresses the above-  
20 discussed first analogue. If the first analogue is equipped with the above-detailed T<sub>H</sub> epitopes and/or first and/or second and/or third moieties, these are then present in the form of fusion partners to the amino acid sequence derived from the polypeptide antigen, the fusion construct being encoded by the  
25 nucleic acid fragment.

As for the traditional vaccination approach, the nucleic acid vaccination can be combined with *in vivo* introduction, into the APC, of at least one nucleic acid fragment encoding and expressing the second analogue. The considerations pertaining  
30 to 1<sup>st</sup>, 2<sup>nd</sup> and 3<sup>rd</sup> moieties and T<sub>H</sub> epitopes apply also here.

In this embodiment, the introduced nucleic acid is preferably DNA which can be in the form of naked DNA, DNA formulated with charged or uncharged lipids, DNA formulated in liposomes, DNA included in a viral vector, DNA formulated with a

5 transfection-facilitating protein or polypeptide, DNA formulated with a targeting protein or polypeptide, DNA formulated with Calcium precipitating agents, DNA coupled to an inert carrier molecule, and DNA formulated with an adjuvant. In this context it is noted that practically all considerations per-

10 taining to the use of adjuvants in traditional vaccine formulation apply for the formulation of DNA vaccines. Hence, all disclosures herein which relate to use of adjuvants in the context of polypeptide based vaccines apply *mutatis mutandis* to their use in nucleic acid vaccination technology. The same

15 holds true for other considerations relating to formulation and mode and route of administration and, hence, also these considerations discussed above in connection with a traditional vaccine apply *mutatis mutandis* to their use in nucleic acid vaccination technology.

20 One especially preferred type of formulation of nucleic acid vaccines are microparticles containing the DNA. Suitable microparticles are e.g. described in WO 98/31398. Further, also here the teachings relating to the use of chitosan formulations as described above apply *mutatis mutandis*.

25 Furthermore, the nucleic acid(s) used as an immunization agent can contain regions encoding the 1<sup>st</sup>, 2<sup>nd</sup> and/or 3<sup>rd</sup> moieties, e.g. in the form of the immunomodulating substances described above such as the cytokines discussed as useful adjuvants. A preferred version of this embodiment encompasses having the

30 coding region for the analogue and the coding region for the immunomodulator in different open reading frames or at least

under the control of different promoters. Thereby it is avoided that the analogue or epitope is produced as a fusion partner to the immunomodulator. Alternatively, two distinct nucleotide fragments can be used, but this is less preferred  
5 because of the advantage of ensured co-expression when having both coding regions included in the same molecule.

Under normal circumstances, the nucleic acid of the vaccine is introduced in the form of a vector wherein expression is under control of a viral promoter. For more detailed discussions of  
10 vectors according to the invention, cf. the discussion below. Also, detailed disclosures relating to the formulation and use of nucleic acid vaccines are available, cf. Donnelly JJ et al, 1997, Annu. Rev. Immunol. 15: 617-648 and Donnelly JJ et al., 1997, Life Sciences 60: 163-172. Both of these references are  
15 incorporated by reference herein.

It should be noted that preferred analogues used in the methods of the invention comprise modifications which results in a polypeptide having a sequence identity of at least 70% with the polypeptide antigen or with a subsequence thereof of  
20 at least 10 amino acids in length. Higher sequence identities are preferred, e.g. at least 75% or even at least 80% or 85%. The sequence identity for proteins and nucleic acids can be calculated as  $(N_{\text{ref}} - N_{\text{dif}}) \cdot 100 / N_{\text{ref}}$ , wherein  $N_{\text{dif}}$  is the total number of non-identical residues in the two sequences when  
25 aligned and wherein  $N_{\text{ref}}$  is the number of residues in one of the sequences. Hence, the DNA sequence AGTCAGTC will have a sequence identity of 75% with the sequence AATCAATC ( $N_{\text{dif}}=2$  and  $N_{\text{ref}}=8$ ).

Antigens and tools used in the invention

Details concerning specific variants of antigens as well as biochemical and biological tools used for their production is discussed in detail in WO 00/20027, which is hereby  
5 incorporated by reference herein. All disclosures in WO 00/20027 pertaining to any of the weak polypeptide antigens mentioned herein pertain equally for the purposes of the present invention - this also includes the specific rationale for choosing these antigens as targets for the presently  
10 claimed therapeutic vaccination method. On pages 55 through 65, WO 00/20027 lists these antigens; the application of the present invention on any one of these antigens is an especially preferred embodiment of the present invention. However, as mentioned above, the present invention is  
15 applicable to any antigen towards which it would be desired to raise a CTL response.


4 of the antigens listed in WO 00/20027 are of special interest, namely PSM, Her2, hCG and FGF8b. These, and all pertinent antigens in the above-referenced table will  
20 eventually be formulated according to the principles of the present invention.

Hence, the method of the invention preferably entails that a foreign T<sub>H</sub>-cell epitope is introduced in a part of the PSM amino acid sequence defined by SEQ ID NO: 2 positions 16-52  
25 and/or 87-108 and/or 210-230 and/or 269-289 and/or 298-324 and/or 442-465 and/or 488-514 and/or 598-630 and/or 643-662 and/or 672-699. Furthermore, a modified PSM molecule which has a foreign T<sub>H</sub>-epitope introduced in these positions is also a part of the invention.

A further important embodiment of the methods of the invention is one wherein the foreign T-cell epitope is introduced in a part of the Her2 amino acid sequence defined by the amino acid numbering in SEQ ID NO: 3 positions 5-25 and/or 59-73 and/or 103-117 and/or 149-163 and/or 210-224 and/or 250-264 and/or 325-339 and/or 369-383 and/or 465-479 and/or 579-593 and/or 632-652 and/or 653-667 and/or 661-675 and/or 695-709 and/or 710-730, cf. the Examples.

Finally, the invention also relates to embodiments of the methods described herein where, where the foreign T-cell epitope is introduced in a part of the FGF8b amino acid sequence defined by SEQ ID NO: 6 positions 1-54 and/or 178-215 and/or 55-58 and/or 63-68 and/or 72-76 and/or 85-91 and/or 95-102 and/or 106-111 and/or 115-120 and/or 128-134 and/or 138-144 and/or 149-154 and/or 158-162 and/or 173-177. It should be noted that it is especially preferred not to introduce variations or modifications in positions 26-45 and in the C-terminus starting at amino acids 186-215, since these stretches show the least homology with a recently discovered protein, FGF-18, which seems to be expressed in a variety of non-tumour tissues.

Furthermore, the present invention also pertains to methods of the invention employing specifically modified versions of the human mucins, especially any of MUC-1 through MUC-4, preferably MUC-1. The analogues comprise the following structure



-where TR is a tandem repeat derived from the naturally occurring mucin, P is a foreign T<sub>H</sub>-epitope as discussed herein, S is an inert spacer peptide having from 0 to 15 amino acid resi-

dues, preferably between 0 and 10 amino acid residues, and n is an integer of from 1 to 30, and m is an integer from 1 to 10, preferably from 3 to 5.

#### Compositions of the invention

- 5 The invention also relates to an immunogenic composition which comprises chitosan as described above and, as a specific part of the immunogenic agent, at least one of the polypeptides or nucleic acid fragments described herein in admixture with a pharmaceutically and immunologically acceptable carrier,  
10 vehicle, diluent, or excipient, and optionally an adjuvant, cf also the discussion of these entities in the description of the method of the invention above.

#### EXAMPLE 1

##### *Preparation of chitosan microparticles*

- 15 0.2 g of chitosan base (ChitoClear™ 804 from Primex Ingredients, Viscosity: 12 mPas measured in 1% in 1% acetic acid, deacetylation: 98.3%) and 0.8 g of Tween 80 is weighed out in a 100 ml beaker and brought into solution by addition of 80 ml of 2% acetic acid and subsequent stirring so as to  
20 obtain a solution of 0.25% chitosan, 1% Tween 80 and 2% acetic acid.

- The beaker is placed in an ultrasound probe device (Soniprep 150, MSE) with a magnet stirring device. The solution is sonicated with a small probe for 30 min at 6 mA and magnetic  
25 stirring. Initially, sodium sulphate solution is added dropwise until particles precipitate (the amount and

concentration can vary, e.g. 2 ml 10% sodium sulphate, 1 ml 20% sulphate etc.).

The particles are spun down in two 50 ml tubes at 5000 rpm for 20 min (Stratos Biofuge, Heraeus Instruments). The supernatant  
5 is isolated and resuspended in MilliQ water. Each batch is pooled in a tube and water is added up to approximately 35 ml. The tubes are centrifuged again. This wash procedure is repeated two more times.

After the 3<sup>rd</sup> wash, 30 ml MilliQ water is added and the  
10 centrifugation is performed at 500 rpm for 10 min in order to remove ultrasound "metal dust". The centrifugation is repeated. The Supernatant is transferred to new 50 ml tubes before centrifuging a 3<sup>rd</sup> time.

A 250 flask is weighed and the mass is noted. 1.5 trehalose  
15 dihydrate is weighed (precisely) out in the flask, corresponding to  $1.5 \times 342.3/378.3$  g trehalose. Thereafter, the 30 ml suspension containing chitosan microparticles is added. The trehalose must be solubilized. The resulting mixture is freeze dried by means of ethanol and dry ice.

20 The following day, the flask is weighed to allow for the calculation of the amount of particles (Second weight of flask minus first weight of flask and weight of trehalose).

## EXAMPLE 2

### *Loading of chitosan microparticles with ovalbumin*

25 Solutions of 20 mg/ml chitosan particles in water are prepared as well as solutions of 20 mg/ml ovalbumin in water. 0.5 ml of

each solution are mixed in an Eppendorf tube which is left to incubate for 3 hours at room temperature.

After 3 hours, the suspension is transferred to a 10 ml tube and 4 ml MilliQ is added. The resulting mixture is centrifuged at 10,000 rpm for 15 min. The supernatant is removed by suction and the pellet is resuspended in 5 ml MilliQ water. The mixture is centrifuged again. This procedure is repeated 3 times. The amount of ovalbumin in the supernatant (i.e. non-bound ovalbumin) is determined by means of a BCA assay:

- 10 A standard solution of ovalbumin in water containing 0.5 mg/ml is prepared. This standard is diluted to 0.4, 0.2, 0.1, 0.05 and 0.0125 mg/ml. 20  $\mu$ l per well of each of these 7 standards as well as a blind are added in triplicate to a flat-bottomed microtiter plate, cf. the scheme below. The supernatants (some in diluted form, cf. the scheme below) from the loading are added at 20  $\mu$ l per well.

|   | 1                | 2 | 3 | 4                            | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|---|------------------|---|---|------------------------------|---|---|---|---|---|----|----|----|
| A | 0.5 mg/ml OVA    |   |   | 1 <sup>st</sup> sup. dil. x2 |   |   |   |   |   |    |    |    |
| B | 0.4 mg/ml OVA    |   |   | 1 <sup>st</sup> sup. dil. x4 |   |   |   |   |   |    |    |    |
| C | 0.2 mg/ml OVA    |   |   | 1 <sup>st</sup> sup. dil. x8 |   |   |   |   |   |    |    |    |
| D | 0.1 mg/ml OVA    |   |   | 2 <sup>nd</sup> sup. dil. x1 |   |   |   |   |   |    |    |    |
| E | 0.05 mg/ml OVA   |   |   | 3 <sup>rd</sup> sup. dil. x1 |   |   |   |   |   |    |    |    |
| F | 0.025 mg/ml OVA  |   |   |                              |   |   |   |   |   |    |    |    |
| G | 0.0125 mg/ml OVA |   |   |                              |   |   |   |   |   |    |    |    |
| H | 0 mg/ml OVA      |   |   |                              |   |   |   |   |   |    |    |    |

200 µl BCA reagent (1 part copper(II) sulphate pentahydrate 4% to 50 parts bicinchoninic acid solution) is added to all wells.

The plate is incubated at approximately 50°C for 30-45 min.

- 5 After cooling to room temperature, the plate is assayed spectrophotometrically at 562 nm.

### EXAMPLE 3

#### *Assaying of CTL induction and T-cell proliferation*

Mice have been injected subcutaneously with the following:

- 10 1. 200 µl ovalbumin-loaded (0.5 µg/ml) chitosan particles prepared as above (10 µg chitosan per 5 µg ovalbumin).
2. 200 µl ovalbumin/chitosan mixture (0.5 µg/ml ovalbumin and approximately same ratio between chitosan and ovalbumin).
3. 200 µl ovalbumin in Freund's complete adjuvant (0.5 µg/ml  
15 ovalbumin).
4. 200 µl of the peptide SIINFEKL (a known CTL epitope from ovalbumin) in Freund's complete adjuvant (0.5 µg/ml SIINFEKL).
5. 200 µl ovalbumin in H<sub>2</sub>O (0.5 µg/ml ovalbumin).
6. 200 µl H<sub>2</sub>O.
- 20 Ten days after last immunization, the mice were sacrificed and axillar and inguinal lymph nodes and the spleens were excised.

In a standard Chrome release assay for determination of CTLs lysing SIINFEKL-carrying cells, results have been obtained showing that CTLs were induced by the albumin-loaded chitosan particles to the same degree as both Ova in FCA and SIINFEKL  
5 in FCA.

Further, in a standard proliferation assay where the specific reactivity of T-cells is gauged, it was shown that the immunization with ovalbumin-loaded chitosan particles results in a proliferation index which is more than 2x higher than that  
10 obtained using ovalbumin in FCA, meaning that the chitosan formulation exhibits a superior capability of inducing antigen-specific T-cell proliferation.

#### EXAMPLE 4

##### *Cross-linking of chitosan sulphate microparticles*

15 In order to obtain a chitosan microparticle formulation with increased stability, the following cross-linking procedure is applied.

25  $\mu$ l of an aqueous glutaraldehyde solution (25%) is added at 25°C at 1000 rpm (Thermomixer compact, Eppendorf, Hamburg,  
20 Germany) to 1 ml of microparticle suspension (0,5% w/v) as prepared above in EXAMPLE 1.

The cross-linking reaction is stopped after 5 minutes by adding 30% (v/v) hydrogen peroxide solution (four times the amount of glutaraldehyde).

25 The cross-linked microparticles are subsequently purified by 3 rounds of centrifugation + resuspension in water.

The microparticle suspension can be non-loaded or protein-loaded microparticles. Cross-linking time and cross-linking agent amount can be varied: Equally good results are obtained when using 10  $\mu$ l of glutaraldehyde and stopping the cross-  
5 linking after 1 hour.

Stability studies have shown that the microparticles obtained by means of this procedure are more stable than the particles obtained directly from Example 1. Currently, immunization experiments corresponding to those of Example 3 are performed  
10 with the cross-linked chitosan formulations in order to confirm that they will also be effective in inducing CTL responses.

## CLAIMS

1. A method for inducing or enhancing an immune response against a polypeptide antigen in an animal, including a human being, said polypeptide antigen being weakly immunogenic or  
5 non-immunogenic in the animal, the method comprising administering, to the animal, the polypeptide antigen or at least one variant thereof which includes at least one first T-helper Cell epitope that is foreign to the animal (foreign T<sub>H</sub> epitope), wherein the polypeptide antigen or variant thereof  
10 is formulated with chitosan.
2. The method of claim 1, which comprises effecting simultaneous presentation by antigen presenting cells (APCs) of the animal's immune system of an immunogenically effective amount of
- 15 1) at least one CTL epitope derived from the polypeptide antigen, and
- 2) the at least one first foreign T<sub>H</sub> epitope.
3. The method according to claim 2 wherein the polypeptide antigen is a cell-associated polypeptide antigen and wherein  
20 the method includes down-regulating the cell-associated polypeptide antigen in the animal by inducing a specific cytotoxic T-lymphocyte (CTL) response against cells carrying the cell-associated polypeptide antigen on their surface or harbouring the cell-associated polypeptide antigen in their  
25 intracellular compartment, the method comprising effecting, in the animal, simultaneous presentation by a suitable antigen presenting cell (APC) of

- 1) at least one CTL epitope derived from the polypeptide antigen, and
  - 2) the at least one first  $T_H$  epitope.
4. The method according to claim 2 or 3, wherein said at least  
5 one CTL epitope when presented is associated with an MHC Class I molecule on the surface of the APC and/or wherein said at least one first foreign  $T_H$  epitope when presented is associated with an MHC Class II molecule on the surface of the APC.
5. The method according to any one of the preceding claims,  
10 wherein the APC is a dendritic cell or a macrophage.
6. The method according to any one of the preceding claims, wherein the polypeptide antigen is selected from a tumour-associated polypeptide antigen, a self-protein, a viral polypeptide antigen, and a polypeptide antigen derived from an  
15 intracellular parasite or bacterium.
7. The method according to any one of claims 2-6, wherein presentation by the APC of the CTL epitope and the first foreign  $T_H$  epitope is effected by presenting the animal's immune system with the variant in the form of at least one  
20 first analogue of the polypeptide antigen, said first analogue comprising a variation of the amino acid sequence of the polypeptide antigen, said variation containing at least the CTL epitope and the first foreign  $T_H$  epitope.
8. The method according to claim 7, wherein the variation  
25 and/or modification involves amino acid substitution and/or deletion and/or insertion and/or addition.

9. The method according to claim 7 or 8, wherein the variation and/or modification comprises that

- at least one first moiety is included in the first analogue, said first moiety effecting targeting of the analogue to an  
5 antigen presenting cell (APC), and/or
- at least one second moiety is included in the first analogue, said second moiety stimulating the immune system, and/or
- at least one third moiety is included in the first analogue,  
10 said third moiety optimizing presentation of the analogue to the immune system.

10. The method according to any one of the preceding claims, wherein the first foreign T<sub>H</sub> epitope is immunodominant and/or wherein the first foreign T<sub>H</sub> epitope is promiscuous.

- 15 11. The method according to any one of the preceding claims, wherein the first foreign T<sub>H</sub> epitope is selected from a natural T<sub>H</sub> epitope and an artificial MHC-II binding peptide sequence.

12. The method according to claim 11, wherein the natural T<sub>H</sub> epitope is selected from a Tetanus toxoid epitope such as P2  
20 or P30, a diphtheria toxoid epitope, an influenza virus hemagglutinin epitope, and a *P. falciparum* CS epitope.

13. The method according to any one of the preceding claims, wherein the first T<sub>H</sub> epitope and/or first and/or second and/or third moieties are present in the form of

- side groups attached covalently or non-covalently to suitable chemical groups in the amino acid sequence of the polypeptide antigen or a subsequence thereof, and/or
- fusion partners to the amino acid sequence derived from the  
5 polypeptide antigen.

14. The method according to claim 13, wherein the first moiety is a substantially specific binding partner for an APC specific surface antigen such as a carbohydrate for which there is a receptor on the APC, e.g. mannan or mannose, wherein the  
10 second moiety is a cytokine selected from interferon  $\gamma$  (IFN- $\gamma$ ), Flt3L, interleukin 1 (IL-1), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 12 (IL-12), interleukin 13 (IL-13), interleukin 15 (IL-15), and granulocyte-macrophage colony stimulating factor (GM-CSF), or  
15 an effective part thereof; a heat-shock protein selected from HSP70, HSP90, HSC70, GRP94, and calreticulin (CRT), or an effective part thereof; or a hormone, and wherein the third moiety is a lipid such as a palmitoyl group, a myristyl group, a farnesyl group, a geranyl-geranyl group, a GPI-anchor, and  
20 an N-acyl diglyceride group.

15. The method according to any one of the preceding claims, wherein the polypeptide antigen or the variant in addition to chitosan is formulated together with a pharmaceutically and immunologically acceptable carrier and/or vehicle and,  
25 optionally an adjuvant.

16. The method according to claim 15, wherein said adjuvant facilitates uptake by APCs, such as dendritic cells, of the polypeptide antigen or variant.

17. The method according to claim 16, wherein the adjuvant is selected from the group consisting of an immune targeting adjuvant; an immune modulating adjuvant such as a toxin, a cytokine, and a mycobacterial derivative; an oil formulation;  
5 a polymer; a micelle forming adjuvant; a saponin; an immunostimulating complex matrix (ISCOM matrix); a particle; DDA; aluminium adjuvants; DNA adjuvants;  $\gamma$ -inulin; and an encapsulating adjuvant.

18. The method according to any one of the preceding claims,  
10 which includes administration via a route selected from the oral route and the parenteral route such as the intradermal, the subdermal, the intracutaneous, the subcutaneous; the peritoneal, the buccal, the sublingual, the epidural, the spinal, the anal, and the intracranial routes.

15 19. The method according to any one of the preceding claims, which includes at least one administration a year, such as at least 2, 3, 4, 5, 6, and 12 administrations a year.

20. The method according to any one of the preceding claims, wherein the weak cell-associated antigen is selected from the  
20 group consisting of 5 alpha reductase,  $\alpha$ -fetoprotein, AM-1, APC, APRIL, BAGE,  $\beta$ -catenin, Bcl2, bcr-abl (b3a2), CA-125, CASP-8 / FLICE, Cathepsins, CD19, CD20, CD21, CD23, CD22, CD33, CD35, CD44, CD45, CD46, CD5, CD52, CD55 (791Tgp72), CD59, CDC27, CDK4, CEA, c-myc, Cox-2, DCC, DcR3, E6 / E7,  
25 EGFR, EMBP, Ena78, farsyl transferase, FGF8a or FGF8b, FLK-1/KDR, Folic Acid Receptor, G250, GAGE-Family, gastrin 17, Gastrin-releasing hormone (Bombesin), GD2 / GD3 / GM2, GnRH, GnTV, GP1, gp100 / Pmel 17, gp-100-in4, gp15, gp75 / TRP-1, hCG, Heparanase, Her2 / neu, HMTV, Hsp70, hTERT (telomerase),  
30 IGFR1, IL-13R, iNOS, Ki 67, KIAA0205, K-ras, H-ras, N-ras, KSA

(CO17-1A), LDLR-FUT, MAGE Family (MAGE-1, MAGE-2, MAGE-3, etc), Mammaglobin, MAP17, Melan-A / MART-1, mesothelin, MIC A/B, MT-MMP's, Mox1, Mucin such as MUC-1, MUC-2, MUC-3, and MUC-4 being abberantly glycosylated, MUM-1, NY-ESO-1,  
5 Osteonectin, p15, P170 / MDR1, p53, p97 / melanotransferrin, PAI-1, PDGF, Plasminogen (uPA), PRAME, Probasin, Progenipoietin, PSA, PSM, RAGE-1, Rb, RCAS1, SART-1, SSX gene family, STAT3, STn (mucin assoc.), TAG-72, TGF- $\alpha$ , TGF- $\beta$ , Thymosin  $\beta$  15, TNF- $\alpha$ , TPA, TPI, TRP-2, Tyrosinase, VEGF, ZAG,  
10 p16INK4, and Glutathione S-transferase.

21. The method according to claim 20, wherein the cell-associated polypeptide antigen is human PSM.

22. The method according to claim 21, wherein the foreign T-cell epitope is introduced in a part of the PSM amino acid  
15 sequence defined by SEQ ID NO: 2 positions 16-52 and/or 87-108 and/or 210-230 and/or 269-289 and/or 298-324 and/or 442-465 and/or 488-514 and/or 598-630 and/or 643-662 and/or 672-699.

23. The method according to claim 21 or 22 used in the treatment or amelioration of prostate cancer.

20 24. The method according to claim 20, wherein the cell-associated polypeptide antigen is fibroblast growth factor 8b (FGF8b).

25 25. The method according to claim 24, where the foreign T-cell epitope is introduced in a part of the FGF8b amino acid sequence defined by SEQ ID NO: 6 positions 1-54 and/or 178-215 and/or 55-58 and/or 63-68 and/or 72-76 and/or 85-91 and/or 95-102 and/or 106-111 and/or 115-120 and/or 128-134 and/or 138-144 and/or 149-154 and/or 158-162 and/or 173-177, and

wherein the introduction preferably does not substantially involve amino acids 26-45 and amino acids 186-215.

26. The method according to claim 24 or 25 used in the treatment or amelioration of cancer such as prostate cancer and  
5 breast cancer.

27. The method according to claim 20, wherein the cell-associated polypeptide antigen is Her2.

28. The method according to claim 27, wherein the foreign T-cell epitope is introduced in a part of the Her2 amino acid  
10 sequence defined by SEQ ID NO: 3 positions 5-25 and/or 59-73 and/or 103-117 and/or 149-163 and/or 210-224 and/or 250-264 and/or 325-339 and/or 369-383 and/or 465-479 and/or 579-593 and/or 632-652 and/or 653-667 and/or 661-675 and/or 695-709 and/or 710-730.

15 29. The method according to claim 27 or 28 used in the treatment or amelioration of breast cancer.

30. The method according to any one of the preceding claims, wherein the polypeptide antigen or the variant thereof is part of a simple mixture with chitosan.

20 31. The method according to any of claims 1-29, wherein the polypeptide antigen or variant thereof is formulated in a chitosan microparticle, such as a bead, microsphere or microcapsule.

32. The method according to claim 30 or 31, wherein the mean  
25 molecular weight of the chitosan molecules used for preparation of the formulation is in the range from about 3,000 to about 3,000,000, preferably in the range from about

30,000 to about 2,000,000, more preferred in the range from about 50,000 to about 500,000, even more preferred in the range from about 60,000 to about 400,000, still more preferred in the range from about 70,000 to about 300,000, especially  
5 preferred in the range from about 80,000 to about 200,000.

33. The method according to claim 32, wherein the mean molecular weight is in the range from about 90,000 to about 150,000, preferably from about 95,000 to about 130,000

34. The method according to any of claims 30-33, wherein the  
10 chitosan used for preparing the formulation has a viscosity, as measured for 1% chitosan in 1% acetic acid, range from about 2 mPas to about 500 mPas, preferably in the range from about 3 to about 300 mPas, more preferred from about 4 to about 200 mPas, even more preferred from about 5 to about 150  
15 mPas, still more preferred from about 6 to about 120 mPas, and even still more preferred from about 7 to about 100 mPas.

35. The method according to claim 34, wherein the viscosity is in the range from about 8 to about 80 mPas, preferably from about 9 to about 60 mPas, even more preferably from about 10 to  
20 about 40 mPas, still more preferably from about 11 to about 20 mPas, and especially in a range close around 12 mPas.

36. The method according to any one of claims 30-35, wherein chitosan used for preparing the formulation has a degree of deacetylation of at least 65%, such as at least 70%, at least  
25 75%, at least 80%, and at least 85%, preferably at least 87%, such as at least 89%, at least 91%, and at least 93%, and more preferred at least 95%, such as at least 97%, and most preferred at least 98%.

37. The method according to any of claims 31 and 32-36 insofar as these are depending on claim 31, wherein the mean diameter of chitosan microparticles is in the range from about 0.1 to about 10  $\mu\text{m}$ , preferably between 0.2 and 5  $\mu\text{m}$ , more preferred 5 between 0.3 and 2.5  $\mu\text{m}$ , especially preferred in the range between 0.4 and 2  $\mu\text{m}$ , and most preferred between 0.5 and 1.5  $\mu\text{m}$ .

38. The method according to claim 37, wherein the mean particle diameter is between 0.6 and 1.3  $\mu\text{m}$ , such as between 10 0.65 and 1.2  $\mu\text{m}$ , especially between 0.7 and 1.0  $\mu\text{m}$ , and preferably between 0.73 and 0.82  $\mu\text{m}$ .

39. The method according to any of claims 31 and 32-38 insofar as these depend on claim 60, wherein the mean  $\zeta$  potential of unloaded chitosan microparticles is in the range from about 15 +0.5 to about +50 mV, such as from about 15 to about 45 mV, from about 20 to about 42 mV, from about 25 to about 41 mV, from about 30 to about 40 mV, from about 33 to about 39 mV, and from about 34 to about 38 mV.

40. The method according to any one of claims 30-39, wherein 20 the ratio (w/w) between chitosan and polypeptide or nucleic acid is in the range between 10 and 1, such as between 8 and 1.3, between 5 and 1.5, between 3 and 1.7, between 2.5 and 1.8, and preferably the ratio is about 2.

41. The method according to any one of claims 30-40, which 25 also comprises a pharmaceutically acceptable amount of a detergent, such as QuilA, listeriolysin, Tween 80 or Tween 20.

42. An immunogenic composition which comprises chitosan in admixture with 1) a polypeptide antigen or variant as these are defined in any one of claims 6-14, 20-22, 24, 25, 27 and

28 and 2) a pharmaceutically and immunologically acceptable carrier or vehicle, and optionally a further adjuvant.


43. The immunogenic composition according to claim 42, wherein the chitosan component is as defined in any one of claims 30-  
5 40.

44. The immunogenic composition according to claim 42 or 43, further comprising a pharmaceutically acceptable amount of a detergent, such as QuilA, listeriolysin, Tween 80 or Tween 20.

45. Use of chitosan in the preparation of an immunogenic  
10 composition for inducing or enhancing an immune response, such as a CTL response, against a protein antigen.

46. Use of chitosan and a polypeptide antigen or a variant thereof for the preparation of an immunogenic composition for inducing or enhancing an immune response, such as a CTL  
15 response, against the polypeptide antigen.

1/2

**Fig. 1**

2/2




Fig. 2

## SEQUENCE LISTING

&lt;110&gt; Pharmexa A/S

&lt;120&gt; NOVEL THERAPEUTIC VACCINE FORMULATIONS

&lt;130&gt; P1011PC00

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 6

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 2253

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(2253)

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (58)..(2253)

&lt;223&gt; Human PSM'

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (4)..(6)

&lt;223&gt; ggt or tgg encoding Gly and Trp, respectively

&lt;400&gt; 1

|   |     |
|---|-----|
| atg ggt aat ctc ctt cac gaa acc gac tcg gct gtg gcc acc gcg cgc | 48  |
| Met Gly Asn Leu Leu His Glu Thr Asp Ser Ala Val Ala Thr Ala Arg |     |
| 1 5 10 15   |     |
| cgc ccg cgc tgg ctg tgc gct ggg gcg ctg gtg ctg gcg ggt ggc ttc | 96  |
| Arg Pro Arg Trp Leu Cys Ala Gly Ala Leu Val Leu Ala Gly Gly Phe |     |
| 20 25 30  |     |
| ttt ctc ctc ggc ttc ctc ttc ggg tgg ttt ata aaa tcc tcc aat gaa | 144 |
| Phe Leu Leu Gly Phe Leu Phe Gly Trp Phe Ile Lys Ser Ser Asn Glu |     |
| 35 40 45  |     |
| gct act aac att act cca aag cat aat atg aaa gca ttt ttg gat gaa | 192 |
| Ala Thr Asn Ile Thr Pro Lys His Asn Met Lys Ala Phe Leu Asp Glu |     |
| 50 55 60  |     |
| ttg aaa gct gag aac atc aag aag ttc tta tat aat ttt aca cag ata | 240 |
| Leu Lys Ala Glu Asn Ile Lys Lys Phe Leu Tyr Asn Phe Thr Gln Ile |     |
| 65 70 75 80   |     |
| cca cat tta gca gga aca gaa caa aac ttt cag ctt gca aag caa att | 288 |
| Pro His Leu Ala Gly Thr Glu Gln Asn Phe Gln Leu Ala Lys Gln Ile |     |
| 85 90 95  |     |

|   |      |
|---|------|
| caa tcc cag tgg aaa gaa ttt ggc ctg gat tct gtt gag cta gca cat | 336  |
| Gln Ser Gln Trp Lys Glu Phe Gly Leu Asp Ser Val Glu Leu Ala His |      |
| 100 105 110   |      |
| tat gat gtc ctg ttg tcc tac cca aat aag act cat ccc aac tac atc | 384  |
| Tyr Asp Val Leu Leu Ser Tyr Pro Asn Lys Thr His Pro Asn Tyr Ile |      |
| 115 120 125   |      |
| tca ata att aat gaa gat gga aat gag att ttc aac aca tca tta ttt | 432  |
| Ser Ile Ile Asn Glu Asp Gly Asn Glu Ile Phe Asn Thr Ser Leu Phe |      |
| 130 135 140   |      |
| gaa cca cct cct cca gga tat gaa aat gtt tcg gat att gta cca cct | 480  |
| Glu Pro Pro Pro Pro Gly Tyr Glu Asn Val Ser Asp Ile Val Pro Pro |      |
| 145 150 155 160   |      |
| ttc agt gct ttc tct cct caa gga atg cca gag ggc gat cta gtg tat | 528  |
| Phe Ser Ala Phe Ser Pro Gln Gly Met Pro Glu Gly Asp Leu Val Tyr |      |
| 165 170 175   |      |
| gtt aac tat gca cga act gaa gac ttc ttt aaa ttg gaa cgg gac atg | 576  |
| Val Asn Tyr Ala Arg Thr Glu Asp Phe Phe Lys Leu Glu Arg Asp Met |      |
| 180 185 190   |      |
| aaa atc aat tgc tct ggg aaa att gta att gcc aga tat ggg aaa gtt | 624  |
| Lys Ile Asn Cys Ser Gly Lys Ile Val Ile Ala Arg Tyr Gly Lys Val |      |
| 195 200 205   |      |
| ttc aga gga aat aag gtt aaa aat gcc cag ctg gca ggg gcc aaa gga | 672  |
| Phe Arg Gly Asn Lys Val Lys Asn Ala Gln Leu Ala Gly Ala Lys Gly |      |
| 210 215 220   |      |
| gtc att ctc tac tcc gac cct gct gac tac ttt gct cct ggg gtg aag | 720  |
| Val Ile Leu Tyr Ser Asp Pro Ala Asp Tyr Phe Ala Pro Gly Val Lys |      |
| 225 230 235 240   |      |
| tcc tat cca gat ggt tgg aat ctt cct gga ggt ggt gtc cag cgt gga | 768  |
| Ser Tyr Pro Asp Gly Trp Asn Leu Pro Gly Gly Gly Val Gln Arg Gly |      |
| 245 250 255   |      |
| aat atc cta aat ctg aat ggt gca gga gac cct ctc aca cca ggt tac | 816  |
| Asn Ile Leu Asn Leu Asn Gly Ala Gly Asp Pro Leu Thr Pro Gly Tyr |      |
| 260 265 270   |      |
| cca gca aat gaa tat gct tat agg cgt gga att gca gag gct gtt ggt | 864  |
| Pro Ala Asn Glu Tyr Ala Tyr Arg Arg Gly Ile Ala Glu Ala Val Gly |      |
| 275 280 285   |      |
| ctt cca agt att cct gtt cat cca att gga tac tat gat gca cag aag | 912  |
| Leu Pro Ser Ile Pro Val His Pro Ile Gly Tyr Tyr Asp Ala Gln Lys |      |
| 290 295 300   |      |
| ctc cta gaa aaa atg ggt ggc tca gca cca cca gat agc agc tgg aga | 960  |
| Leu Leu Glu Lys Met Gly Ser Ala Pro Pro Asp Ser Ser Trp Arg     |      |
| 305 310 315 320   |      |
| gga agt ctc aaa gtg ccc tac aat gtt gga cct ggc ttt act gga aac | 1008 |
| Gly Ser Leu Lys Val Pro Tyr Asn Val Gly Pro Gly Phe Thr Gly Asn |      |
| 325 330 335   |      |

|   |      |
|---|------|
| ttt tct aca caa aaa gtc aag atg cac atc cac tct acc aat gaa gtg | 1056 |
| Phe Ser Thr Gln Lys Val Lys Met His Ile His Ser Thr Asn Glu Val |      |
| 340 345 350   |      |
| aca aga att tac aat gtg ata ggt act ctc aga gga gca gtg gaa cca | 1104 |
| Thr Arg Ile Tyr Asn Val Ile Gly Thr Leu Arg Gly Ala Val Glu Pro |      |
| 355 360 365   |      |
| gac aga tat gtc att ctg gga ggt cac cgg gac tca tgg gtg ttt ggt | 1152 |
| Asp Arg Tyr Val Ile Leu Gly Gly His Arg Asp Ser Trp Val Phe Gly |      |
| 370 375 380   |      |
| ggg att gac cct cag agt gga gca gct gtt gtt cat gaa att gtg agg | 1200 |
| Gly Ile Asp Pro Gln Ser Gly Ala Ala Val Val His Glu Ile Val Arg |      |
| 385 390 395 400   |      |
| agc ttt gga aca ctg aaa aag gaa ggg tgg aga cct aga aga aca att | 1248 |
| Ser Phe Gly Thr Leu Lys Lys Glu Gly Trp Arg Pro Arg Arg Thr Ile |      |
| 405 410 415   |      |
| ttg ttt gca agc tgg gat gca gaa gaa ttt ggt ctt ctt ggt tct act | 1296 |
| Leu Phe Ala Ser Trp Asp Ala Glu Glu Phe Gly Leu Leu Gly Ser Thr |      |
| 420 425 430   |      |
| gag tgg gca gag gag aat tca aga ctc ctt caa gag cgt ggc gtg gct | 1344 |
| Glu Trp Ala Glu Glu Asn Ser Arg Leu Leu Gln Glu Arg Gly Val Ala |      |
| 435 440 445   |      |
| tat att aat gct gac tca tct ata gaa gga aac tac act ctg aga gtt | 1392 |
| Tyr Ile Asn Ala Asp Ser Ser Ile Glu Gly Asn Tyr Thr Leu Arg Val |      |
| 450 455 460   |      |
| gat tgt aca ccg ctg atg tac agc ttg gta cac aac cta aca aaa gag | 1440 |
| Asp Cys Thr Pro Leu Met Tyr Ser Leu Val His Asn Leu Thr Lys Glu |      |
| 465 470 475 480   |      |
| ctg aaa agc cct gat gaa ggc ttt gaa ggc aaa tct ctt tat gaa agt | 1488 |
| Leu Lys Ser Pro Asp Glu Gly Phe Glu Gly Lys Ser Leu Tyr Glu Ser |      |
| 485 490 495   |      |
| tgg act aaa aaa agt cct tcc cca gag ttc agt ggc atg ccc agg ata | 1536 |
| Trp Thr Lys Lys Ser Pro Ser Pro Glu Phe Ser Gly Met Pro Arg Ile |      |
| 500 505 510   |      |
| agc aaa ttg gga tct gga aat gat ttt gag gtg ttc ttc caa cga ctt | 1584 |
| Ser Lys Leu Gly Ser Gly Asn Asp Phe Glu Val Phe Phe Gln Arg Leu |      |
| 515 520 525   |      |
| gga att gct tca ggc aga gca cgg tat act aaa aat tgg gaa aca aac | 1632 |
| Gly Ile Ala Ser Gly Arg Ala Arg Tyr Thr Lys Asn Trp Glu Thr Asn |      |
| 530 535 540   |      |
| aaa ttc agc ggc tat cca ctg tat cac agt gtc tat gaa aca tat gag | 1680 |
| Lys Phe Ser Gly Tyr Pro Leu Tyr His Ser Val Tyr Glu Thr Tyr Glu |      |
| 545 550 555 560   |      |

```

ttg gtg gaa aag ttt tat gat cca atg ttt aaa tat cac ctc act gtg 1728
Leu Val Glu Lys Phe Tyr Asp Pro Met Phe Lys Tyr His Leu Thr Val
                    565                      570                      575

gcc cag gtt cga gga ggg atg gtg ttt gag cta gcc aat tcc ata gtg 1776
Ala Gln Val Arg Gly Gly Met Val Phe Glu Leu Ala Asn Ser Ile Val
                    580                      585                      590

ctc cct ttt gat tgt cga gat tat gct gta gtt tta aga aag tat gct 1824
Leu Pro Phe Asp Cys Arg Asp Tyr Ala Val Val Leu Arg Lys Tyr Ala
                    595                      600                      605

gac aaa atc tac agt att tct atg aaa cat cca cag gaa atg aag aca 1872
Asp Lys Ile Tyr Ser Ile Ser Met Lys His Pro Gln Glu Met Lys Thr
                    610                      615                      620

tac agt gta tca ttt gat tca ctt ttt tct gca gta aag aat ttt aca 1920
Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr
625                      630                      635                      640

gaa att gct tcc aag ttc agt gag aga ctc cag gac ttt gac aaa agc 1968
Glu Ile Ala Ser Lys Phe Ser Glu Arg Leu Gln Asp Phe Asp Lys Ser
                    645                      650                      655

aac cca ata gta tta aga atg atg aat gat caa ctc atg ttt ctg gaa 2016
Asn Pro Ile Val Leu Arg Met Met Asn Asp Gln Leu Met Phe Leu Glu
                    660                      665                      670

aga gca ttt att gat cca tta ggg tta cca gac agg cct ttt tat agg 2064
Arg Ala Phe Ile Asp Pro Leu Gly Leu Pro Asp Arg Pro Phe Tyr Arg
                    675                      680                      685

cat gtc atc tat gct cca agc agc cac aac aag tat gca ggg gag tca 2112
His Val Ile Tyr Ala Pro Ser Ser His Asn Lys Tyr Ala Gly Glu Ser
690                      695                      700

ttc cca gga att tat gat gct ctg ttt gat att gaa agc aaa gtg gac 2160
Phe Pro Gly Ile Tyr Asp Ala Leu Phe Asp Ile Glu Ser Lys Val Asp
705                      710                      715                      720

cct tcc aag gcc tgg gga gaa gtg aag aga cag att tat gtt gca gcc 2208
Pro Ser Lys Ala Trp Gly Glu Val Lys Arg Gln Ile Tyr Val Ala Ala
                    725                      730                      735

ttc aca gtg cag gca gct gca gag act ttg agt gaa gta gcc taa 2253
Phe Thr Val Gln Ala Ala Ala Glu Thr Leu Ser Glu Val Ala
                    740                      745                      750

```

&lt;210&gt; 2

&lt;211&gt; 750

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

Met Gly Asn Leu Leu His Glu Thr Asp Ser Ala Val Ala Thr Ala Arg
  1                      5                      10                      15

```

Arg Pro Arg Trp Leu Cys Ala Gly Ala Leu Val Leu Ala Gly Gly Phe  
                   20                  25                  30  
 Phe Leu Leu Gly Phe Leu Phe Gly Trp Phe Ile Lys Ser Ser Asn Glu  
                   35                  40                  45  
 Ala Thr Asn Ile Thr Pro Lys His Asn Met Lys Ala Phe Leu Asp Glu  
                   50                  55                  60  
 Leu Lys Ala Glu Asn Ile Lys Lys Phe Leu Tyr Asn Phe Thr Gln Ile  
                   65                  70                  75                  80  
 Pro His Leu Ala Gly Thr Glu Gln Asn Phe Gln Leu Ala Lys Gln Ile  
                   85                  90  
 Gln Ser Gln Trp Lys Glu Phe Gly Leu Asp Ser Val Glu Leu Ala His  
                   100                  105                  110  
 Tyr Asp Val Leu Leu Ser Tyr Pro Asn Lys Thr His Pro Asn Tyr Ile  
                   115                  120                  125  
 Ser Ile Ile Asn Glu Asp Gly Asn Glu Ile Phe Asn Thr Ser Leu Phe  
                   130                  135                  140  
 Glu Pro Pro Pro Pro Gly Tyr Glu Asn Val Ser Asp Ile Val Pro Pro  
                   145                  150                  155                  160  
 Phe Ser Ala Phe Ser Pro Gln Gly Met Pro Glu Gly Asp Leu Val Tyr  
                   165                  170                  175  
 Val Asn Tyr Ala Arg Thr Glu Asp Phe Phe Lys Leu Glu Arg Asp Met  
                   180                  185                  190  
 Lys Ile Asn Cys Ser Gly Lys Ile Val Ile Ala Arg Tyr Gly Lys Val  
                   195                  200                  205  
 Phe Arg Gly Asn Lys Val Lys Asn Ala Gln Leu Ala Gly Ala Lys Gly  
                   210                  215                  220  
 Val Ile Leu Tyr Ser Asp Pro Ala Asp Tyr Phe Ala Pro Gly Val Lys  
                   225                  230                  235                  240  
 Ser Tyr Pro Asp Gly Trp Asn Leu Pro Gly Gly Gly Val Gln Arg Gly  
                   245                  250                  255  
 Asn Ile Leu Asn Leu Asn Gly Ala Gly Asp Pro Leu Thr Pro Gly Tyr  
                   260                  265                  270  
  
 Pro Ala Asn Glu Tyr Ala Tyr Arg Arg Gly Ile Ala Glu Ala Val Gly  
                   275                  280                  285  
 Leu Pro Ser Ile Pro Val His Pro Ile Gly Tyr Tyr Asp Ala Gln Lys  
                   290                  295                  300  
 Leu Leu Glu Lys Met Gly Gly Ser Ala Pro Pro Asp Ser Ser Trp Arg  
                   305                  310                  315                  320

Gly Ser Leu Lys Val Pro Tyr Asn Val Gly Pro Gly Phe Thr Gly Asn  
 325 330 335  
 Phe Ser Thr Gln Lys Val Lys Met His Ile His Ser Thr Asn Glu Val  
 340 345 350  
 Thr Arg Ile Tyr Asn Val Ile Gly Thr Leu Arg Gly Ala Val Glu Pro  
 355 360 365  
 Asp Arg Tyr Val Ile Leu Gly Gly His Arg Asp Ser Trp Val Phe Gly  
 370 375 380  
 Gly Ile Asp Pro Gln Ser Gly Ala Ala Val Val His Glu Ile Val Arg  
 385 390 395 400  
 Ser Phe Gly Thr Leu Lys Lys Glu Gly Trp Arg Pro Arg Arg Thr Ile  
 405 410 415  
 Leu Phe Ala Ser Trp Asp Ala Glu Glu Phe Gly Leu Leu Gly Ser Thr  
 420 425 430  
 Glu Trp Ala Glu Glu Asn Ser Arg Leu Leu Gln Glu Arg Gly Val Ala  
 435 440 445  
 Tyr Ile Asn Ala Asp Ser Ser Ile Glu Gly Asn Tyr Thr Leu Arg Val  
 450 455 460  
 Asp Cys Thr Pro Leu Met Tyr Ser Leu Val His Asn Leu Thr Lys Glu  
 465 470 475 480  
 Leu Lys Ser Pro Asp Glu Gly Phe Glu Gly Lys Ser Leu Tyr Glu Ser  
 485 490 495  
 Trp Thr Lys Lys Ser Pro Ser Pro Glu Phe Ser Gly Met Pro Arg Ile  
 500 505 510  
 Ser Lys Leu Gly Ser Gly Asn Asp Phe Glu Val Phe Phe Gln Arg Leu  
 515 520 525  
 Gly Ile Ala Ser Gly Arg Ala Arg Tyr Thr Lys Asn Trp Glu Thr Asn  
 530 535 540  
 Lys Phe Ser Gly Tyr Pro Leu Tyr His Ser Val Tyr Glu Thr Tyr Glu  
 545 550 555 560  
 Leu Val Glu Lys Phe Tyr Asp Pro Met Phe Lys Tyr His Leu Thr Val  
 565 570 575  
 Ala Gln Val Arg Gly Gly Met Val Phe Glu Leu Ala Asn Ser Ile Val  
 580 585 590  
 Leu Pro Phe Asp Cys Arg Asp Tyr Ala Val Val Leu Arg Lys Tyr Ala  
 595 600 605  
 Asp Lys Ile Tyr Ser Ile Ser Met Lys His Pro Gln Glu Met Lys Thr  
 610 615 620  
 Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr  
 625 630 635 640

Glu Ile Ala Ser Lys Phe Ser Glu Arg Leu Gln Asp Phe Asp Lys Ser  
                     645                    650                    655  
 Asn Pro Ile Val Leu Arg Met Met Asn Asp Gln Leu Met Phe Leu Glu  
                     660                    665                    670  
 Arg Ala Phe Ile Asp Pro Leu Gly Leu Pro Asp Arg Pro Phe Tyr Arg  
                     675                    680                    685  
 His Val Ile Tyr Ala Pro Ser Ser His Asn Lys Tyr Ala Gly Glu Ser  
                     690                    695                    700  
 Phe Pro Gly Ile Tyr Asp Ala Leu Phe Asp Ile Glu Ser Lys Val Asp  
 705                    710                    715                    720  
 Pro Ser Lys Ala Trp Gly Glu Val Lys Arg Gln Ile Tyr Val Ala Ala  
                     725                    730                    735  
 Phe Thr Val Gln Ala Ala Ala Glu Thr Leu Ser Glu Val Ala  
                     740                    745                    750

<210> 3  
 <211> 3768  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (1)..(3768)

<400> 3  
 atg gag ctg gcg gcc ttg tgc cgc tgg ggg ctc ctc ctc gcc ctc ttg 48  
 Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu  
                     -20                    -15                    -10  
 ccc ccc gga gcc gcg agc acc caa gtg tgc acc ggc aca gac atg aag 96  
 Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Met Lys  
                     -5                    -1    1                    5  
 ctg cgg ctc cct gcc agt ccc gag acc cac ctg gac atg ctc cgc cac 144  
 Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His  
                     10                    15                    20                    25  
 ctc tac cag ggc tgc cag gtg gtg cag gga aac ctg gaa ctc acc tac 192  
 Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr  
                     30                    35                    40  
 ctg ccc acc aat gcc agc ctg tcc ttc ctg cag gat atc cag gag gtg 240  
 Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val  
                     45                    50                    55  
 cag ggc tac gtg ctc atc gct cac aac caa gtg agg cag gtc cca ctg 288  
 Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val Pro Leu  
                     60                    65                    70

|   |      |
|---|------|
| cag agg ctg cgg att gtg cga ggc acc cag ctc ttt gag gac aac tat | 336  |
| Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr |      |
| 75 80 85  |      |
| gcc ctg gcc gtg cta gac aat gga gac ccg ctg aac aat acc acc cct | 384  |
| Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro |      |
| 90 95 100 105   |      |
| gtc aca ggg gcc tcc cca gga ggc ctg cgg gag ctg cag ctt cga agc | 432  |
| Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser |      |
| 110 115 120   |      |
| ctc aca gag atc ttg aaa gga ggg gtc ttg atc cag cgg aac ccc cag | 480  |
| Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln |      |
| 125 130 135   |      |
| ctc tgc tac cag gac acg att ttg tgg aag gac atc ttc cac aag aac | 528  |
| Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn |      |
| 140 145 150   |      |
| aac cag ctg gct ctc aca ctg ata gac acc aac cgc tct cgg gcc tgc | 576  |
| Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys |      |
| 155 160 165   |      |
| cac ccc tgt tct ccg atg tgt aag ggc tcc cgc tgc tgg gga gag agt | 624  |
| His Pro Cys Ser Pro Met Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser |      |
| 170 175 180 185   |      |
| tct gag gat tgt cag agc ctg acg cgc act gtc tgt gcc ggt ggc tgt | 672  |
| Ser Glu Asp Cys Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys     |      |
| 190 195 200   |      |
| gcc cgc tgc aag ggg cca ctg ccc act gac tgc tgc cat gag cag tgt | 720  |
| Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys |      |
| 205 210 215   |      |
| gct gcc ggc tgc acg ggc ccc aag cac tct gac tgc ctg gcc tgc ctc | 768  |
| Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu |      |
| 220 225 230   |      |
| cac ttc aac cac agt ggc atc tgt gag ctg cac tgc cca gcc ctg gtc | 816  |
| His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val |      |
| 235 240 245   |      |
| acc tac aac aca gac acg ttt gag tcc atg ccc aat ccc gag ggc cgg | 864  |
| Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro Glu Gly Arg |      |
| 250 255 260 265   |      |
| tat aca ttc ggc gcc agc tgt gtg act gcc tgt ccc tac aac tac ctt | 912  |
| Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Tyr Leu |      |
| 270 275 280   |      |
| tct acg gac gtg gga tcc tgc acc ctc gtc tgc ccc ctg cac aac caa | 960  |
| Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln |      |
| 285 290 295   |      |
| gag gtg aca gca gag gat gga aca cag cgg tgt gag aag tgc agc aag | 1008 |
| Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys |      |
| 300 305 310   |      |

|   |      |
|---|------|
| ccc tgt gcc cga gtg tgc tat ggt ctg ggc atg gag cac ttg cga gag | 1056 |
| Pro Cys Ala Arg Val Cys Tyr Gly Leu Gly Met Glu His Leu Arg Glu |      |
| 315 320 325   |      |
| gtg agg gca gtt acc agt gcc aat atc cag gag ttt gct ggc tgc aag | 1104 |
| Val Arg Ala Val Thr Ser Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys |      |
| 330 335 340 345   |      |
| aag atc ttt ggg agc ctg gca ttt ctg ccg gag agc ttt gat ggg gac | 1152 |
| Lys Ile Phe Gly Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp |      |
| 350 355 360   |      |
| cca gcc tcc aac act gcc ccg ctc cag cca gag cag ctc caa gtg ttt | 1200 |
| Pro Ala Ser Asn Thr Ala Pro Leu Gln Pro Glu Gln Leu Gln Val Phe |      |
| 365 370 375   |      |
| gag act ctg gaa gag atc aca ggt tac cta tac atc tca gca tgg ccg | 1248 |
| Glu Thr Leu Glu Glu Ile Thr Gly Tyr Leu Tyr Ile Ser Ala Trp Pro |      |
| 380 385 390   |      |
| gac agc ctg cct gac ctc agc gtc ttc cag aac ctg caa gta atc cgg | 1296 |
| Asp Ser Leu Pro Asp Leu Ser Val Phe Gln Asn Leu Gln Val Ile Arg |      |
| 395 400 405   |      |
| gga cga att ctg cac aat ggc gcc tac tgc ctg acc ctg caa ggg ctg | 1344 |
| Gly Arg Ile Leu His Asn Gly Ala Tyr Ser Leu Thr Leu Gln Gly Leu |      |
| 410 415 420 425   |      |
| ggc atc agc tgg ctg ggg ctg cgc tca ctg agg gaa ctg ggc agt gga | 1392 |
| Gly Ile Ser Trp Leu Gly Leu Arg Ser Leu Arg Glu Leu Gly Ser Gly |      |
| 430 435 440   |      |
| ctg gcc ctc atc cac cat aac acc cac ctc tgc ttc gtg cac acg gtg | 1440 |
| Leu Ala Leu Ile His His Asn Thr His Leu Cys Phe Val His Thr Val |      |
| 445 450 455   |      |
| ccc tgg gac cag ctc ttt cgg aac ccg cac caa gct ctg ctc cac act | 1488 |
| Pro Trp Asp Gln Leu Phe Arg Asn Pro His Gln Ala Leu Leu His Thr |      |
| 460 465 470   |      |
| gcc aac cgg cca gag gac gag tgt gtg ggc gag ggc ctg gcc tgc cac | 1536 |
| Ala Asn Arg Pro Glu Asp Glu Cys Val Gly Glu Gly Leu Ala Cys His |      |
| 475 480 485   |      |
| cag ctg tgc gcc cga ggg cac tgc tgg ggt cca ggg ccc acc cag tgt | 1584 |
| Gln Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly Pro Thr Gln Cys |      |
| 490 495 500 505   |      |
| gtc aac tgc agc cag ttc ctt cgg ggc cag gag tgc gtg gag gaa tgc | 1632 |
| Val Asn Cys Ser Gln Phe Leu Arg Gly Gln Glu Cys Val Glu Glu Cys |      |
| 510 515 520   |      |
| cga gta ctg cag ggg ctc ccc agg gag tat gtg aat gcc agg cac tgt | 1680 |
| Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr Val Asn Ala Arg His Cys |      |
| 525 530 535   |      |
| ttg ccg tgc cac cct gag tgt cag ccc cag aat ggc tca gtg acc tgt | 1728 |
| Leu Pro Cys His Pro Glu Cys Gln Pro Gln Asn Gly Ser Val Thr Cys |      |
| 540 545 550   |      |

|  |      |
|--|------|
| ttt gga ccg gag gct gac cag tgt gtg gcc tgt gcc cac tat aag gac              | 1776 |
| Phe Gly Pro Glu Ala Asp Gln Cys Val Ala Cys Ala His Tyr Lys Asp              |      |
| 555 560 565  |      |
| cct ccc ttc tgc gtg gcc cgc tgc ccc agc ggt gtg aaa cct gac ctc              | 1824 |
| Pro Pro Phe Cys Val Ala Arg Cys Pro Ser Gly Val Lys Pro Asp Leu              |      |
| 570 575 580 585  |      |
| tcc tac atg ccc atc tgg aag ttt cca gat gag gag ggc gca tgc cag              | 1872 |
| Ser Tyr Met Pro Ile Trp Lys Phe Pro Asp Glu Glu Gly Ala Cys Gln              |      |
| 590 595 600  |      |
| cct tgc ccc atc aac tgc acc cac tcc tgt gtg gac ctg gat gac aag              | 1920 |
| Pro Cys Pro Ile Asn Cys Thr His Ser Cys Val Asp Leu Asp Asp Lys              |      |
| 605 610 615  |      |
| ggc tgc ccc gcc gag cag aga gcc agc cct ctg acg tcc atc gtc tct              | 1968 |
| Gly Cys Pro Ala Glu Gln Arg Ala Ser Pro Leu Thr Ser Ile Val Ser              |      |
| 620 625 630  |      |
| gcg gtg gtt ggc att ctg ctg gtc gtg gtc ttg ggg gtg gtc ttt ggg              | 2016 |
| Ala Val Val Gly Ile Leu Leu Val Val Val Leu Gly Val Val Phe Gly              |      |
| 635 640 645  |      |
| atc ctc atc aag cga cgg cag cag aag atc cgg aag tac acg atg cgg              | 2064 |
| Ile Leu Ile Lys Arg Arg Gln Gln Lys Ile Arg Lys Tyr Thr Met Arg              |      |
| 650 655 660 665  |      |
| aga ctg ctg cag gaa acg gag ctg gtg gag ccg ctg aca cct agc gga              | 2112 |
| Arg Leu Leu Gln Glu Thr Glu Leu Val Glu Pro Leu Thr Pro Ser Gly              |      |
| 670 675 680  |      |
| gcg atg ccc aac cag gcg cag atg cgg atc ctg aaa gag acg gag ctg              | 2160 |
| Ala Met Pro Asn Gln Ala Gln Met Arg Ile Leu Lys Glu Thr Glu Leu              |      |
| 685 690 695  |      |
| agg aag gtg aag gtg ctt gga tct ggc gct ttt ggc aca gtc tac aag              | 2208 |
| Arg Lys Val Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys              |      |
| 700 705 710  |      |
| ggc atc tgg atc cct gat ggg gag aat gtg aaa att cca gtg gcc atc              | 2256 |
| Gly Ile Trp Ile Pro Asp Gly Glu Asn Val Lys Ile <sup>o</sup> Pro Val Ala Ile |      |
| 715 720 725  |      |
| aaa gtg ttg agg gaa aac aca tcc ccc aaa gcc aac aaa gaa atc tta              | 2304 |
| Lys Val Leu Arg Glu Asn Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu              |      |
| 730 735 740 745  |      |
| gac gaa gca tac gtg atg gct ggt gtg ggc tcc cca tat gtc tcc cgc              | 2352 |
| Asp Glu Ala Tyr Val Met Ala Gly Val Gly Ser Pro Tyr Val Ser Arg              |      |
| 750 755 760  |      |
| ctt ctg ggc atc tgc ctg aca tcc acg gtg cag ctg gtg aca cag ctt              | 2400 |
| Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val Thr Gln Leu              |      |
| 765 770 775  |      |

|   |      |
|---|------|
| atg ccc tat ggc tgc ctc tta gac cat gtc cgg gaa aac cgc gga cgc | 2448 |
| Met Pro Tyr Gly Cys Leu Leu Asp His Val Arg Glu Asn Arg Gly Arg |      |
| 780 785 790   |      |
| ctg ggc tcc cag gac ctg ctg aac tgg tgt atg cag att gcc aag ggg | 2496 |
| Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys Met Gln Ile Ala Lys Gly |      |
| 795 800 805   |      |
| atg agc tac ctg gag gat gtg cgg ctc gta cac agg gac ttg gcc gct | 2544 |
| Met Ser Tyr Leu Glu Asp Val Arg Leu Val His Arg Asp Leu Ala Ala |      |
| 810 815 820 825   |      |
| cgg aac gtg ctg gtc aag agt ccc aac cat gtc aaa att aca gac ttc | 2592 |
| Arg Asn Val Leu Val Lys Ser Pro Asn His Val Lys Ile Thr Asp Phe |      |
| 830 835 840   |      |
| ggg ctg gct cgg ctg ctg gac att gac gag aca gag tac cat gca gat | 2640 |
| Gly Leu Ala Arg Leu Leu Asp Ile Asp Glu Thr Glu Tyr His Ala Asp |      |
| 845 850 855   |      |
| ggg ggc aag gtg ccc atc aag tgg atg gcg ctg gag tcc att ctc cgc | 2688 |
| Gly Gly Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser Ile Leu Arg |      |
| 860 865 870   |      |
| cgg cgg ttc acc cac cag agt gat gtg tgg agt tat ggt gtg act gtg | 2736 |
| Arg Arg Phe Thr His Gln Ser Asp Val Trp Ser Tyr Gly Val Thr Val |      |
| 875 880 885   |      |
| tgg gag ctg atg act ttt ggg gcc aaa cct tac gat ggg atc cca gcc | 2784 |
| Trp Glu Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly Ile Pro Ala |      |
| 890 895 900 905   |      |
| cgg gag atc cct gac ctg ctg gaa aag ggg gag cgg ctg ccc cag ccc | 2832 |
| Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro |      |
| 910 915 920   |      |
| ccc atc tgc acc att gat gtc tac atg atc atg gtc aaa tgt tgg atg | 2880 |
| Pro Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val Lys Cys Trp Met |      |
| 925 930 935   |      |
| att gac tct gaa tgt cgg cca aga ttc cgg gag ttg gtg tct gaa ttc | 2928 |
| Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg Glu Leu Val Ser Glu Phe |      |
| 940 945 950   |      |
| tcc cgc atg gcc agg gac ccc cag cgc ttt gtg gtc atc cag aat gag | 2976 |
| Ser Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile Gln Asn Glu |      |
| 955 960 965   |      |
| gac ttg ggc cca gcc agt ccc ttg gac agc acc ttc tac cgc tca ctg | 3024 |
| Asp Leu Gly Pro Ala Ser Pro Leu Asp Ser Thr Phe Tyr Arg Ser Leu |      |
| 970 975 980 985   |      |
| ctg gag gac gat gac atg ggg gac ctg gtg gat gct gag gag tat ctg | 3072 |
| Leu Glu Asp Asp Asp Met Gly Asp Leu Val Asp Ala Glu Glu Tyr Leu |      |
| 990 995 1000  |      |
| gta ccc cag cag ggc ttc ttc tgt cca gac cct gcc ccg ggc gct ggg | 3120 |
| Val Pro Gln Gln Gly Phe Phe Cys Pro Asp Pro Ala Pro Gly Ala Gly |      |
| 1005 1010 1015  |      |

ggc atg gtc cac cac agg cac cgc agc tca tct acc agg agt ggc ggt 3168  
 Gly Met Val His His Arg His Arg Ser Ser Ser Thr Arg Ser Gly Gly  
 1020 1025 1030

ggg gac ctg aca cta ggg ctg gag ccc tct gaa gag gag gcc ccc agg 3216  
 Gly Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu Glu Glu Ala Pro Arg  
 1035 1040 1045

tct cca ctg gca ccc tcc gaa ggg gct ggc tcc gat gta ttt gat ggt 3264  
 Ser Pro Leu Ala Pro Ser Glu Gly Ala Gly Ser Asp Val Phe Asp Gly  
 1050 1055 1060 1065

gac ctg gga atg ggg gca gcc aag ggg ctg caa agc ctc ccc aca cat 3312  
 Asp Leu Gly Met Gly Ala Ala Lys Gly Leu Gln Ser Leu Pro Thr His  
 1070 1075 1080

gac ccc agc cct cta cag cgg tac agt gag gac ccc aca gta ccc ctg 3360  
 Asp Pro Ser Pro Leu Gln Arg Tyr Ser Glu Asp Pro Thr Val Pro Leu  
 1085 1090 1095

ccc tct gag act gat ggc tac gtt gcc ccc ctg acc tgc agc ccc cag 3408  
 Pro Ser Glu Thr Asp Gly Tyr Val Ala Pro Leu Thr Cys Ser Pro Gln  
 1100 1105 1110

cct gaa tat gtg aac cag cca gat gtt cgg ccc cag ccc cct tcg ccc 3456  
 Pro Glu Tyr Val Asn Gln Pro Asp Val Arg Pro Gln Pro Pro Ser Pro  
 1115 1120 1125

cga gag ggc cct ctg cct gct gcc cga cct gct ggt gcc act ctg gaa 3504  
 Arg Glu Gly Pro Leu Pro Ala Ala Arg Pro Ala Gly Ala Thr Leu Glu  
 1130 1135 1140 1145

agg gcc aag act ctc tcc cca ggg aag aat ggg gtc gtc aaa gac gtt 3552  
 Arg Ala Lys Thr Leu Ser Pro Gly Lys Asn Gly Val Val Lys Asp Val  
 1150 1155 1160

ttt gcc ttt ggg ggt gcc gtg gag aac ccc gag tac ttg aca ccc cag 3600  
 Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr Leu Thr Pro Gln  
 1165 1170 1175

gga gga gct gcc cct cag ccc cac cct cct cct gcc ttc agc cca gcc 3648  
 Gly Gly Ala Ala Pro Gln Pro His Pro Pro Pro Ala Phe Ser Pro Ala  
 1180 1185 1190

ttc gac aac ctc tat tac tgg gac cag gac cca cca gag cgg ggg gct 3696  
 Phe Asp Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Pro Glu Arg Gly Ala  
 1195 1200 1205

cca ccc agc acc ttc aaa ggg aca cct acg gca gag aac cca gag tac 3744  
 Pro Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala Glu Asn Pro Glu Tyr  
 1210 1215 1220 1225

ctg ggt ctg gac gtg cca gtg tga 3768  
 Leu Gly Leu Asp Val Pro Val  
 1230

&lt;211&gt; 1255

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

```

Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu
 1          5          10          15

Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Met Lys
          20          25          30

Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His
 35          40          45

Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr
 50          55          60

Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val
 65          70          75          80

Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val Pro Leu
          85          90          95

Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr
          100          105          110

Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro
          115          120          125

Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser
          130          135          140

Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln
          145          150          155          160

Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn
          165          170          175

Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys
          180          185          190

His Pro Cys Ser Pro Met Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser
          195          200          205

Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys
          210          215          220

Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys
          225          230          235          240

Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu
          245          250          255

His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val
          260          265          270

Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro Glu Gly Arg
          275          280          285

```

Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Tyr Leu  
 290 295 300  
 Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln  
 305 310 315 320  
 Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys  
 325 330 335  
 Pro Cys Ala Arg Val Cys Tyr Gly Leu Gly Met Glu His Leu Arg Glu  
 340 345 350  
 Val Arg Ala Val Thr Ser Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys  
 355 360 365  
 Lys Ile Phe Gly Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp  
 370 375 380  
 Pro Ala Ser Asn Thr Ala Pro Leu Gln Pro Glu Gln Leu Gln Val Phe  
 385 390 395 400  
 Glu Thr Leu Glu Glu Ile Thr Gly Tyr Leu Tyr Ile Ser Ala Trp Pro  
 405 410 415  
 Asp Ser Leu Pro Asp Leu Ser Val Phe Gln Asn Leu Gln Val Ile Arg  
 420 425 430  
 Gly Arg Ile Leu His Asn Gly Ala Tyr Ser Leu Thr Leu Gln Gly Leu  
 435 440 445  
 Gly Ile Ser Trp Leu Gly Leu Arg Ser Leu Arg Glu Leu Gly Ser Gly  
 450 455 460  
 Leu Ala Leu Ile His His Asn Thr His Leu Cys Phe Val His Thr Val  
 465 470 475 480  
 Pro Trp Asp Gln Leu Phe Arg Asn Pro His Gln Ala Leu Leu His Thr  
 485 490 495  
 Ala Asn Arg Pro Glu Asp Glu Cys Val Gly Glu Gly Leu Ala Cys His  
 500 505 510  
 Gln Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly Pro Thr Gln Cys  
 515 520 525  
 Val Asn Cys Ser Gln Phe Leu Arg Gly Gln Glu Cys Val Glu Glu Cys  
 530 535 540  
 Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr Val Asn Ala Arg His Cys  
 545 550 555 560  
 Leu Pro Cys His Pro Glu Cys Gln Pro Gln Asn Gly Ser Val Thr Cys  
 565 570 575  
 Phe Gly Pro Glu Ala Asp Gln Cys Val Ala Cys Ala His Tyr Lys Asp  
 580 585 590  
 Pro Pro Phe Cys Val Ala Arg Cys Pro Ser Gly Val Lys Pro Asp Leu  
 595 600 605

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Tyr | Met | Pro | Ile | Trp | Lys | Phe | Pro | Asp | Glu | Glu | Gly | Ala | Cys | Gln |
| 610 |     |     |     |     |     | 615 |     |     |     |     | 620 |     |     |     |     |
| Pro | Cys | Pro | Ile | Asn | Cys | Thr | His | Ser | Cys | Val | Asp | Leu | Asp | Asp | Lys |
| 625 |     |     |     |     | 630 |     |     |     |     | 635 |     |     |     |     | 640 |
| Gly | Cys | Pro | Ala | Glu | Gln | Arg | Ala | Ser | Pro | Leu | Thr | Ser | Ile | Val | Ser |
|     |     |     |     | 645 |     |     |     |     | 650 |     |     |     |     | 655 |     |
| Ala | Val | Val | Gly | Ile | Leu | Leu | Val | Val | Val | Leu | Gly | Val | Val | Phe | Gly |
|     |     |     | 660 |     |     |     |     | 665 |     |     |     |     | 670 |     |     |
| Ile | Leu | Ile | Lys | Arg | Arg | Gln | Gln | Lys | Ile | Arg | Lys | Tyr | Thr | Met | Arg |
|     |     | 675 |     |     |     |     | 680 |     |     |     |     | 685 |     |     |     |
| Arg | Leu | Leu | Gln | Glu | Thr | Glu | Leu | Val | Glu | Pro | Leu | Thr | Pro | Ser | Gly |
|     | 690 |     |     |     |     | 695 |     |     |     |     | 700 |     |     |     |     |
| Ala | Met | Pro | Asn | Gln | Ala | Gln | Met | Arg | Ile | Leu | Lys | Glu | Thr | Glu | Leu |
| 705 |     |     |     |     | 710 |     |     |     |     | 715 |     |     |     |     | 720 |
| Arg | Lys | Val | Lys | Val | Leu | Gly | Ser | Gly | Ala | Phe | Gly | Thr | Val | Tyr | Lys |
|     |     |     |     | 725 |     |     |     |     | 730 |     |     |     |     | 735 |     |
| Gly | Ile | Trp | Ile | Pro | Asp | Gly | Glu | Asn | Val | Lys | Ile | Pro | Val | Ala | Ile |
|     |     |     | 740 |     |     |     |     | 745 |     |     |     |     | 750 |     |     |
| Lys | Val | Leu | Arg | Glu | Asn | Thr | Ser | Pro | Lys | Ala | Asn | Lys | Glu | Ile | Leu |
|     |     | 755 |     |     |     |     | 760 |     |     |     |     | 765 |     |     |     |
| Asp | Glu | Ala | Tyr | Val | Met | Ala | Gly | Val | Gly | Ser | Pro | Tyr | Val | Ser | Arg |
|     | 770 |     |     |     |     | 775 |     |     |     |     | 780 |     |     |     |     |
| Leu | Leu | Gly | Ile | Cys | Leu | Thr | Ser | Thr | Val | Gln | Leu | Val | Thr | Gln | Leu |
| 785 |     |     |     |     | 790 |     |     |     |     | 795 |     |     |     |     | 800 |
| Met | Pro | Tyr | Gly | Cys | Leu | Leu | Asp | His | Val | Arg | Glu | Asn | Arg | Gly | Arg |
|     |     |     |     | 805 |     |     |     |     | 810 |     |     |     |     | 815 |     |
| Leu | Gly | Ser | Gln | Asp | Leu | Leu | Asn | Trp | Cys | Met | Gln | Ile | Ala | Lys | Gly |
|     |     |     | 820 |     |     |     |     | 825 |     |     |     |     | 830 |     |     |
| Met | Ser | Tyr | Leu | Glu | Asp | Val | Arg | Leu | Val | His | Arg | Asp | Leu | Ala | Ala |
|     |     | 835 |     |     |     |     | 840 |     |     |     |     | 845 |     |     |     |
| Arg | Asn | Val | Leu | Val | Lys | Ser | Pro | Asn | His | Val | Lys | Ile | Thr | Asp | Phe |
|     |     |     |     |     |     | 855 |     |     |     |     | 860 |     |     |     |     |
| Gly | Leu | Ala | Arg | Leu | Leu | Asp | Ile | Asp | Glu | Thr | Glu | Tyr | His | Ala | Asp |
| 865 |     |     |     |     | 870 |     |     |     |     | 875 |     |     |     |     | 880 |
| Gly | Gly | Lys | Val | Pro | Ile | Lys | Trp | Met | Ala | Leu | Glu | Ser | Ile | Leu | Arg |
|     |     |     |     | 885 |     |     |     |     | 890 |     |     |     |     | 895 |     |
| Arg | Arg | Phe | Thr | His | Gln | Ser | Asp | Val | Trp | Ser | Tyr | Gly | Val | Thr | Val |
|     |     |     | 900 |     |     |     |     | 905 |     |     |     |     | 910 |     |     |

Trp Glu Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly Ile Pro Ala  
 915 920 925  
 Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro  
 930 935 940  
 Pro Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val Lys Cys Trp Met  
 945 950 955 960  
 Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg Glu Leu Val Ser Glu Phe  
 965 970 975  
 Ser Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile Gln Asn Glu  
 980 985 990  
 Asp Leu Gly Pro Ala Ser Pro Leu Asp Ser Thr Phe Tyr Arg Ser Leu  
 995 1000 1005  
 Leu Glu Asp Asp Asp Met Gly Asp Leu Val Asp Ala Glu Glu Tyr Leu  
 1010 1015 1020  
 Val Pro Gln Gln Gly Phe Phe Cys Pro Asp Pro Ala Pro Gly Ala Gly  
 1025 1030 1035 1040  
 Gly Met Val His His Arg His Arg Ser Ser Ser Thr Arg Ser Gly Gly  
 1045 1050 1055  
 Gly Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu Glu Glu Ala Pro Arg  
 1060 1065 1070  
 Ser Pro Leu Ala Pro Ser Glu Gly Ala Gly Ser Asp Val Phe Asp Gly  
 1075 1080 1085  
 Asp Leu Gly Met Gly Ala Ala Lys Gly Leu Gln Ser Leu Pro Thr His  
 1090 1095 1100  
 Asp Pro Ser Pro Leu Gln Arg Tyr Ser Glu Asp Pro Thr Val Pro Leu  
 1105 1110 1115 1120  
 Pro Ser Glu Thr Asp Gly Tyr Val Ala Pro Leu Thr Cys Ser Pro Gln  
 1125 1130 1135  
 Pro Glu Tyr Val Asn Gln Pro Asp Val Arg Pro Gln Pro Pro Ser Pro  
 1140 1145 1150  
 Arg Glu Gly Pro Leu Pro Ala Ala Arg Pro Ala Gly Ala Thr Leu Glu  
 1155 1160 1165  
 Arg Ala Lys Thr Leu Ser Pro Gly Lys Asn Gly Val Val Lys Asp Val  
 1170 1175 1180  
 Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr Leu Thr Pro Gln  
 1185 1190 1195 1200  
 Gly Gly Ala Ala Pro Gln Pro His Pro Pro Pro Ala Phe Ser Pro Ala  
 1205 1210 1215  
 Phe Asp Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Pro Glu Arg Gly Ala  
 1220 1225 1230

Pro Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala Glu Asn Pro Glu Tyr  
1235 1240 1245

Leu Gly Leu Asp Val Pro Val  
1250 1255

```
<210> 5
<211> 648
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> CDS
<222> (1) .. (648)
```

|   |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|---|-----|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| <400>   | 5   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| atg ggc agc ccc cgc tcc gcg ctg agc tgc ctg ctg ttg cac ttg ctg | 48  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Met Gly Ser Pro Arg Ser Ala Leu Ser Cys Leu Leu Leu His Leu Leu |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 1 5 10 15   |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| gtt ctc tgc ctc caa gcc cag gta act gtt cag tcc tca cct aat ttt | 96  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Val Leu Cys Leu Gln Ala Gln Val Thr Val Gln Ser Ser Pro Asn Phe |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 20 25 30  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| aca cag cat gtg agg gag cag agc ctg gtg acg gat cag ctc agc cgc | 144 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Thr Gln His Val Arg Glu Gln Ser Leu Val Thr Asp Gln Leu Ser Arg |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 35 40 45  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| cgc ctc atc cgg acc tac cag ctc tac agc cgc acc agc ggg aag cac | 192 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Arg Leu Ile Arg Thr Tyr Gln Leu Tyr Ser Arg Thr Ser Gly Lys His |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 50 55 60  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| gtg cag gtc ctg gcc aac aag cgc atc aac gcc atg gca gaa gac gga | 240 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Val Gln Val Leu Ala Asn Lys Arg Ile Asn Ala Met Ala Glu Asp Gly |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 65 70 75 80   |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| gac ccc ttc gcg aag ctc att gtg gag acc gat act ttt gga agc aga | 288 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Asp Pro Phe Ala Lys Leu Ile Val Glu Thr Asp Thr Phe Gly Ser Arg |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 85 90 95  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| gtc cga gtt cgc ggc gca gag aca ggt ctc tac atc tgc atg aac aag | 336 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Val Arg Val Arg Gly Ala Glu Thr Gly Leu Tyr Ile Cys Met Asn Lys |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 100 105 110   |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| aag ggg aag cta att gcc aag agc aac ggc aaa ggc aag gac tgc gta | 384 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Lys Gly Lys Leu Ile Ala Lys Ser Asn Gly Lys Gly Lys Asp Cys Val |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 115 120 125   |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ttc aca gag atc gtg ctg gag aac aac tac acg gcg ctg cag aac gcc | 432 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Phe Thr Glu Ile Val Leu Glu Asn Asn Tyr Thr Ala Leu Gln Asn Ala |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 130 135 140   |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| aag tac gag ggc tgg tac atg gcc ttt acc cgc aag ggc cgg ccc cgc | 480 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Lys Tyr Glu Gly Trp Tyr Met Ala Phe Thr Arg Lys Gly Arg Pro Arg |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 145 150 155 160   |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

18

```

aag ggc tcc aag acg cgc cag cat cag cgc gag gtg cac ttc atg aag 528
Lys Gly Ser Lys Thr Arg Gln His Gln Arg Glu Val His Phe Met Lys
                      165                      170                      175

cgc ctg ccg cgg ggc cac cac acc acc gag cag agc ctg cgc ttc gag 576
Arg Leu Pro Arg Gly His His Thr Thr Glu Gln Ser Leu Arg Phe Glu
                      180                      185                      190

ttc ctc aac tac ccg ccc ttc acg cgc agc ctg cgc ggc agc cag agg 624
Phe Leu Asn Tyr Pro Pro Phe Thr Arg Ser Leu Arg Gly Ser Gln Arg
                      195                      200                      205

act tgg gcc ccg gag ccc cga tag 648
Thr Trp Ala Pro Glu Pro Arg
                      210                      215

```

```

<210> 6
<211> 215
<212> PRT
<213> Homo sapiens

```

```

<400> 6
Met Gly Ser Pro Arg Ser Ala Leu Ser Cys Leu Leu Leu His Leu Leu
 1                      5                      10                      15

Val Leu Cys Leu Gln Ala Gln Val Thr Val Gln Ser Ser Pro Asn Phe
                20                      25                      30

Thr Gln His Val Arg Glu Gln Ser Leu Val Thr Asp Gln Leu Ser Arg
                35                      40                      45

Arg Leu Ile Arg Thr Tyr Gln Leu Tyr Ser Arg Thr Ser Gly Lys His
 50                      55                      60

Val Gln Val Leu Ala Asn Lys Arg Ile Asn Ala Met Ala Glu Asp Gly
 65                      70                      75                      80

Asp Pro Phe Ala Lys Leu Ile Val Glu Thr Asp Thr Phe Gly Ser Arg
                85                      90                      95

Val Arg Val Arg Gly Ala Glu Thr Gly Leu Tyr Ile Cys Met Asn Lys
                100                      105                      110

Lys Gly Lys Leu Ile Ala Lys Ser Asn Gly Lys Gly Lys Asp Cys Val
                115                      120                      125

Phe Thr Glu Ile Val Leu Glu Asn Asn Tyr Thr Ala Leu Gln Asn Ala
                130                      135                      140

Lys Tyr Glu Gly Trp Tyr Met Ala Phe Thr Arg Lys Gly Arg Pro Arg
145                      150                      155                      160

Lys Gly Ser Lys Thr Arg Gln His Gln Arg Glu Val His Phe Met Lys
                165                      170                      175

Arg Leu Pro Arg Gly His His Thr Thr Glu Gln Ser Leu Arg Phe Glu
                180                      185                      190

```



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 May 2002 (02.05.2002)

PCT

(10) International Publication Number  
**WO 02/034287 A3**

- (51) International Patent Classification<sup>7</sup>: **A61K 39/39**
- (21) International Application Number: PCT/DK01/00705
- (22) International Filing Date: 26 October 2001 (26.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
PA 2000 01606 27 October 2000 (27.10.2000) DK  
60/245,166 3 November 2000 (03.11.2000) US  
PA 2001 00936 18 June 2001 (18.06.2001) DK
- (71) Applicant (for all designated States except US):  
**PHARMEXA A/S** [DK/DK]; Kogle Allé 6, DK-2970  
Hørsholm (DK).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BEIER, Anne, Mette** [DK/DK]; c/o Pharmexa A/S, Kogle Allé 6, DK-2970 Hørsholm (DK). **GAUTAM, Anand** [GB/DK]; c/o Pharmexa A/S, Kogle Allé 6, DK-2970 Hørsholm (DK). **MOURITSEN, Søren** [DK/DK]; c/o Pharmexa A/S, Kogle Allé 6, DK-2970 Hørsholm (DK).
- (74) Agent: **KOEFOED, Peter**; c/o Pharmexa A/S, Kogle Allé 6, DK-2970 Hørsholm (DK).
- (81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
16 January 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/034287 A3

(54) Title: THERAPEUTIC VACCINE FORMULATIONS CONTAINING CHITOSAN

(57) Abstract: The present invention relates to a novel method and formulation for the induction of immune responses against polypeptide antigens. In particular, the invention provides a method and formulation for induction of cytotoxic T cell responses against a polypeptide antigen of choice. The formulations are characterized by containing chitosan in admixture with the polypeptide antigen, preferably in the form of microparticles that may be cross-linked.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 01/00705

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K39/39

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

WPI Data, PAJ, BIOSIS, MEDLINE, EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| X          | NISHIMURA K ET AL: "ADJUVANT ACTIVITY OF CHITIN DERIVATIVES IN MICE AND GUINEA-PIGS" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 3, no. 5, 1 December 1985 (1985-12-01), pages 379-384, XP002017432 ISSN: 0264-410X page 382 "discussion" lines 1-3.<br>--- | 1-46                  |
| X          | EP 0 183 556 A (IHARA CHEMICAL IND CO) 4 June 1986 (1986-06-04) page 9, line 18 - line 25<br>---<br>-/--   | 1-46                  |

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the International filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the International filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the International search

2 August 2002

Date of mailing of the International search report

16. 08. 2002

Name and mailing address of the ISA

European Patent Office, P.B. 6818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Anna Björklund

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/DK 01/00705

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |   |                       |
|--|---|-----------------------|
| Category *   | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
| X  | WO 97 20576 A (DANBIOSYST UK ;ILLUM<br>LISBETH (GB)) 12 June 1997 (1997-06-12)<br>page 3, line 4 - line 6<br>page 4, line 19 - line 21<br>page 5, line 21 - line 24<br>claim 21 | 1-46                  |
| A  | ---<br>WO 00 20027 A (M & E BIOTECH A S )<br>13 April 2000 (2000-04-13)<br>claims<br>-----  | 1-46                  |

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/DK 01/00705

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-41  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box I.1

Claims Nos.: 1-41

Claims 1-41 relate to methods of treatment of the human or animal body by surgery or by therapy / diagnostic methods practised on the human or animal body / Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/ compositions.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK 01/00705

| Patent document<br>cited in search report |   | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---|---------------------|----------------------------|---------------------|
| EP 0183556                                | A | 04-06-1986          | JP 1887855 C               | 22-11-1994          |
|   |   |                     | JP 6015476 B               | 02-03-1994          |
|   |   |                     | JP 61268626 A              | 28-11-1986          |
|   |   |                     | JP 1791018 C               | 29-09-1993          |
|   |   |                     | JP 4081967 B               | 25-12-1992          |
|   |   |                     | JP 61130230 A              | 18-06-1986          |
|   |   |                     | CA 1261264 A1              | 26-09-1989          |
|   |   |                     | DE 3583217 D1              | 18-07-1991          |
|   |   |                     | DK 550685 A ,B,            | 30-05-1986          |
|   |   |                     | EP 0183556 A2              | 04-06-1986          |
|   |   |                     | JP 1992379 C               | 22-11-1995          |
|   |   |                     | JP 7023313 B               | 15-03-1995          |
|   |   |                     | JP 62123123 A              | 04-06-1987          |
|   |   |                     | US 4971956 A               | 20-11-1990          |
| WO 9720576                                | A | 12-06-1997          | AU 705452 B2               | 20-05-1999          |
|   |   |                     | AU 1102597 A               | 27-06-1997          |
|   |   |                     | CA 2237529 A1              | 12-06-1997          |
|   |   |                     | EP 0865297 A1              | 23-09-1998          |
|   |   |                     | WO 9720576 A1              | 12-06-1997          |
|   |   |                     | GB 2322801 A ,B            | 09-09-1998          |
|   |   |                     | JP 2000501412 T            | 08-02-2000          |
|   |   |                     | NO 982497 A                | 02-06-1998          |
|   |   |                     | US 6391318 B1              | 21-05-2002          |
| WO 0020027                                | A | 13-04-2000          | AU 5851099 A               | 26-04-2000          |
|   |   |                     | CN 1323217 T               | 21-11-2001          |
|   |   |                     | WO 0020027 A2              | 13-04-2000          |
|   |   |                     | EP 1117421 A2              | 25-07-2001          |
|   |   |                     | NO 20011586 A              | 31-05-2001          |
|   |   |                     | PL 347977 A1               | 06-05-2002          |
|   |   |                     | TR 200100936 T2            | 21-08-2001          |